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Abstract
Heparin sulfate finds itself widely used as an anticoagulant within
medicine. However, only one rescue agent for it exists, protamine
sulfate. Protamine sulfate is an arginine-rich cationic peptide, and
its use within medicine is fraught with issues and a substantial
proportion of patients will experience side effects from its use. Gene
therapy has the potential to cure a variety of genetic disorders
including Cystic Fibrosis. Viral DNA vectors work well, but there
are significant safety concerns, hence the interest in the
development of an effective non-viral vector method.
The work in this thesis synthesised a stereoisomeric family of novel
palmitic acid based cationic binders using a self-assembled
multivalency (SAMul) approach. This family of novel binders
comprises of two enantiomeric pairs, which were synthesised using
a previously reported TBTU-mediated peptide coupling strategy
and repeated Boc-(de)protection steps to afford control over the
regioselectivity of the synthesis. Through the use of 1H, 13C and
DEPT-135 NMR alongside Infrared spectroscopy and Mass
Spectrometry analysis, it has been shown that the target compounds
have successfully been synthesised. Significant analysis of the
behaviour of these SAMul systems has been performed via a series
of binding assays, as well as Transmission Electron Microscopy,
Dynamic Light Scattering and Isothermal Titration Calorimetry.
It has been determined that all four novel binders undergo
self-assembly in solution, and this self-assembly is a prerequisite for
successful heparin sulfate and/or DNA binding. All four systems
bind both heparin sulfate and DNA at micromolar effective
concentrations, much lower than the CAC obtained by Nile Red,
which implies the presence of the biological polyanion enhances
binding affinity. It has also been noted that there is a preference for
D-lysine on binding DNA, but for heparin the preference is much
less pronounced. Finally, the binder:DNA aggregates imaged by
TEM are small enough that they may successfully undergo
endocytosis into mammalian cells and hence could be useful DNA
transfection agents.
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Chapter 1
Introduction
1.1 Heparin Sulfate
Heparin sulfate is a linear oligosaccharide composed mostly of 1,4
linked uronic acid and glucosamine units. It is the most complex
member of the glycosaminoglycan family, with a molecular weight
approximately between 2,500 and 25,000 Da. A specific
pentasaccharide sequence is necessary to give heparin its
anticoagulant ability (Figure 1.1). Consequently, up to 70% of a
single dose of heparin will remain inactive. Despite the natural
biological roles of heparin being poorly understood, it has been
used medically as an anticoagulant from as early as 1935.[1]
OO
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OSO3 NHSO3
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NHSO3
O3SO O
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FIGURE 1.1: Pentasaccharide sequence which gives
heparin its characteristic anticoagulant properties.
Adapted from [1, 2]
There are two separate pathways which control coagulation, as
shown in Figure 1.2, “extrinsic” (tissue factor pathway) and
“intrinsic” (contact activation pathway), and a pathway which is
common to both; unsurprisingly called the common pathway.[3]
Heparin works by binding to both an enzyme inhibitor known as
1
Intrinsic Pathway
(Contact activation)
Surface contact
XII XIIa
XI XIa
IX IXa
X Xa X
ThrombinProthrombin
Fibrin
Cross-linked 
Blood clot
Fibrinogen
VIIa VII
Tissue factor
Tissue damage
Extrinsic Pathway
(Tissue factor)
Common Pathway
ATIII
FIGURE 1.2: The 3 pathways in the coagulation cas-
cade. Roman numerals are used to identify coagula-
tion factors. Adapted from [4–6]
antithrombin III and if the heparin chain is more than 18
pentasaccharides long, it binds to factor Xa as well.[6] This then
prevents prothrombin from being converted into thrombin, and
interferes with the function of the so-called “common” pathway; a
blood clot cannot be formed.
1.1.1 Medical Applications of Heparin Sulfate
Heparin sulfate finds itself used for a variety of reasons within
medicine, most notably as an anticoagulant during major surgery,
whether this be during the insertion of a stent to hold cardiac
arteries open after a myocardial infarction or during major
transplant surgery. In this case, heparin is used to prevent
coagulation inside the extracorporeal circuit.[7]
It also finds use as prophylactic treatment for deep vein thrombosis
(DVT), even though heparin sulfate cannot break down clots which
have already formed, and is used as an additive in the green topped
vacutainer vials used in phlebotomy where heparin is used as its
lithium salt to prevent coagulation of blood samples.[7]
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1.1.2 Issues Associated with Heparin Use
There are a variety of well-known issues with using heparin as an
anticoagulant. Firstly; as already mentioned, a high proportion of
heparin lacks the necessary pentasaccharide sequence that provides
its characteristic anticoagulant activity. This causes issues when it is
necessary that the total heparin load1 is known. Quantifying
heparin levels is typically achieved during surgery via an activated
clotting time assay. These clotting time based assays are very good
at measuring the amount of heparin that is active, but cannot easily
determine the heparin load.
Secondly, there is an issue with the clotting time based assays
themselves. They are slow, and importantly, cannot be performed in
situ.[1]
Finally, it is known that not all heparin preparations are the same.
Differences arise from the origin of the heparin preparation i.e.
bovine vs porcine, in terms of both the structure of the isolated
heparin, and its activity.[8] Bovine sourced heparin can be isolated
from both lung and intestinal tissue, whilst porcine sourced heparin
is exclusively from intestinal tissue.[9] Both forms of heparin are
often used as if they were indistinguishable in their structure and
activity, despite the fact heparin of porcine origin has much higher
activity, and hence smaller quantities can be used. Heparin is
provided clinically simply in terms of ’units of activity’, with little
attention paid to the inactive material.
It is important to note that since the 1980’s, all licensed heparin
products used within the European Union and USA have been of
porcine origin, due to the possibility of transmitting variant
Creutzfeld-Jakob disease (vCJD) via heparin of bovine origin.[8]
1.2 Protamine Sulfate
Protamine sulfate is an arginine-rich cationic peptide of ill-defined
structure, often derived from salmon sperm, that is used medically
1Heparin load - total amount of heparin administered. Includes both the active
and inactive parts of heparin.
Heparin dose - total amount of active heparin. Measured in international units
(IU).
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to reverse the anticoagulant behaviour of heparin.[1, 10] Due to issues
with the clotting time based assays outlined above, dosing
protamine for use as a heparin rescue agent at the end of surgery, is
difficult. Dose too much, and the patient will clot too well,
potentially be at risk of blood clots forming as well as increasing the
risk of developing side effects from protamine sulfate, dose too little
and the patient will not clot sufficiently well that healing can begin.
Finally, the way that protamine itself binds heparin is also
problematic, as it makes no distinction between active and inactive
parts of heparin, which then leads to larger doses of protamine
sulfate being necessary, and hence a greater likelihood of side effects
being experienced. Up to 10% of all those given this rescue agent
will have some form of side effect, and those most at risk include
those who have had previous treatment with protamine sulfate,
insulin-dependent diabetics who take long acting forms containing
protamine sulfate, those with a fish allergy and men who are
infertile.[1, 7]
1.2.1 Binding of Protamine Sulfate to Heparin
The use of protamine sulfate as a rescue agent for heparin is fraught
with issues: from the difficulty in dosing, due to the non-selective
way it binds to heparin, to the side effect known as heparin rebound
first noted by Kolff et al. in 1956, where not enough protamine
sulfate has been dosed, and as heparin unbinds from plasma
proteins, a de-coagulation event and bleeding occurs.[11] Despite
this, protamine sulphate remains the only rescue agent for heparin
to gain clinical approval.
The binding of protamine sulfate to heparin, which abolishes its
anticoagulant ability is based on electrostatic binding. Clearly this
opens the possibility of developing systems which can exhibit more
selective heparin binding, and potentially only bind to the active
polysaccharide sequence, whilst avoiding the side effects associated
with the current use of protamine sulfate.
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1.3 DNA
Deoxyribonucleic acid (DNA) contains a varying composition of 4
specific nucleotide bases (guanine, cytosine, adenine and thymine),
as well as deoxyribose sugars connected by phosphodiester bonds
forming the characteristic sugar-phosphate backbone of DNA.[12]
Hydrogen bonding between these nucleotide bases forms
Watson-Crick base pairs (G with C and A with T) and leads to the
characteristic double stranded helix known as B-DNA.[13] This
B-DNA form has a repeating pattern of wide major grooves, and
narrower minor grooves on its surface, in which a variety of
molecules can bind (Figure 1.3).
FIGURE 1.3: The repeating pattern of major and minor
grooves in B-DNA. From [14].
Heparin sulfate however, is very different to DNA. It is a linear
oligosaccharide of varying composition and length, and as such,
adopts a very different secondary structure to DNA, instead
choosing to form long chains. Even though there are differences
between the roles that DNA and heparin sulfate play within the
human body, one being an incredibly important molecule with a
well defined, regular structure, which contains all the genetic
material necessary for any given living organism; the other being of
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irregular polymeric structure and used as an anticoagulant, there
are similarities between them. Both heparin with its sulfate groups
and DNA with phosphate groups are biologically relevant
polyanionic molecules.[8]
There has been much research into DNA, due to the interest in gene
therapy for a variety of congenital disorders not limited to, but
including Cystic Fibrosis. In contrast, there has been comparatively
little study of the binding of heparin sulfate to protamine, and even
less which attempts to compare and contrast the two.
1.3.1 Binding DNA and Gene Therapy
Small molecules can either interact with DNA in a covalent, or
non-covalent fashion. Covalent binding to DNA results in a
permanent change in the shape of the DNA binding site, whilst
non-covalent interactions are often reversible.[12] These potentially
reversible non-covalent interactions include intercalation between
base pairs, electrostatic interactions with the phosphodiester
backbone of DNA or interactions with the functional groups of the
base pairs in either the major or minor grooves (Table 1.1).[12, 15]
TABLE 1.1: A selection of major/minor-groove
binders and DNA intercalating agents
Major-groove binder Minor-groove binder Intercalating agent
Methyl Green Distamycin A Ethidium Bromide
Methylene Blue
It has also been shown by Broggini et al., that the two grooves do
not behave independently, as binding distamycin A into the
minor-groove leads to interference with the major-groove binding
of various regulatory proteins.[16]
Gene therapy has the potential to cure cancer, and genetic disorders
of both congenital and acquired origin. For this to be possible, it
requires nucleic acids to be transported across the cell membrane by
some form of vector, as DNA cannot translocate across cell
membranes unaided.[17] Viral vector methods work well, but there
are significant safety concerns with the use of these methods for
gene delivery, e.g. the ability of the vector to revert to wild type, or
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replication competent virions, the risk of inherent immunogenicity
as well as the vector causing an inflammatory response.[17, 18]
A variety of synthetic vectors have been developed, often based
upon polymers, dendrimers or liposomes. These synthetic vectors
avoid some of the issues associated with viral methods, but often
suffer from poor loading of genetic material. It is also often difficult
to achieve nuclear uptake after cell penetration. It also must be
noted that a relatively high molecular weight of the synthetic vector
is necessary to lead to effective condensation of DNA, and this high
molecular weight often leads to these synthetic systems being
cytotoxic. There are a variety of cationic polymers which are
capable of binding DNA. These include poly-L-lysine (PLL),
polyethyleneimine (PEI) as well as PAMAM dendrimers. PLL has
been used as a DNA delivery agent for over 20 years due to its
relative biocompatibility, and the ease at which it can be degraded
by cells.[19]
Cationic lipids have also been used to deliver DNA inside cells.
They were first pioneered by Felgner et al. in the late 1980’s and
after further studies, several of these cationic lipid systems are now
commercially available.[20, 21] DOTMA
(N-[1(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride)
is now sold under the trade name Lipofectin, and DOSPA
(2,3-dioleyloxy-N-[2(sperminecarboxido)ethyl]-N,N,-dimethyl-1-
propanaminium trifuloroacetate) is sold as
Lipofectamine.[22, 23]
There are a variety of challenges synthetic vectors must overcome
before they can be used as viable transfection methods; these
include effective complexation and condensation of the DNA,
cellular uptake, and more importantly, endosomal escape as well as
nuclear translocation.[17] Without successful endosomal escape and
translocation, the DNA will be transported inside the cell, but not
reach the nucleus. More recently, CRISPR (Clustered Regularly
Interspaced Short Palindromic Repeat)/Cas9 (CRISPR associated
gene 9) has been employed as a potential method of genetic
delivery. However, once the DNA has been delivered, the CRISPR
genes stay behind in the host cell. This has the potential to cause
unwanted gene editing - clearly problematic in therapeutic
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applications, and there is the possibility of immunogenic responses
in the host.[24] Various strategies of using CRISPR for genetic editing
have been reported in the literature, but they often result in
endosomal entrapment of Cas9 and/or single guide RNA
(sgRNA).[25, 26]
1.3.2 Gene Delivery in Cystic Fibrosis
Cystic Fibrosis (CF) is a congenital genetic disorder where sufferers
receive a faulty copy of the gene which codes for the CFTR (Cystic
Fibrosis Transmembrane Conductance Regulator) protein from both
parents. The CFTR gene was not identified until 1989, since then
more than 2000 different mutations have been identified.[27] These
mutations can be sorted into 6 different classes, based on the type of
malfunction within the CFTR protein. These mutations differ in the
organs that are involved, with lung involvement being most
variable. They also differ in the severity of the disorder and the rate
of progression. However, these classes cannot be used to predict an
individual’s outcome with Cystic Fibrosis, as such, these classes are
of more use within clinical trials.
Several theories exist as to how a malfunctioning CFTR protein
leads to the symptoms associated with CF. The most accredited
theory states: malfunctioning CFTR protein leads to a lack of water
in pericilliary fluid and results in abnormally dense mucus. This
mucus is then difficult for the cillia to clear. This faulty protein then
causes an increased inflammatory response and decreased activity
of natural defense mechanisms, which unsurprisingly facilitates the
development of the symptoms traditionally associated with the
disorder, such as repeated lower respiratory tract infections.
Research is currently focused on treatments for restoring the
function of the CFTR protein, some of which have shown promising
results in clinical trials.[27] One way of achieving this would be
through intracellular delivery of a correctly functioning copy of the
affected gene.
As genetic therapy advances ever closer towards clinical
application, several clinical trials have assessed the potential
benefits for a variety of genetic disorders. A small double-blind
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study involving 140 CF sufferers was undertaken in 2012 to prove
the viability of using inhaled gene-liposome complexes as a
potential treatment for some of the respiratory symptoms associated
with Cystic Fibrosis.[28] The results show that this certainly isn’t a
cure for the disorder, but did prevent some decline in lung function.
It was noted that further clinical studies of gene delivery vehicles
for CF were urgently needed, as this trial did not select participants
with a particular type of CFTR mutation, nor could it explain why
one group of patients - particularly those with a predicted FEV1
(forced expiratory volume in 1 second) of <69.2 % had a greater
response than those who were less unwell.
1.4 Multivalent Interactions and
Self-Assembly
In order to bind nanoscale polymeric structures such as heparin or
DNA, it is necessary to marshal multiple non-covalent interactions -
so called multivalency. As outlined above, systems which can do
this may have potential applications in both heparin rescue and/or
gene delivery. The cationic polymers and dendrimer systems
discussed previously, have been shown to function as potential
protamine sulfate mimics, but their toxicity makes medical
application unlikely. Also, for even the most simple, first-generation
(G1) dendrimers, they often have complex, multi-step syntheses.[29]
Due to the difficulty of constructing a covalent array of ligands to
bind to a specific target, there has been increasing interest in using
self-assembly to organise the multivalent ligands.
The phenomenon of self assembled multivalency was first reported
in 1992 by Whitesides and coworkers in a paper outlining self
assembled sugars that bound better to a sugar binding protein than
their monovalent counterparts. The polyvalent system is more
efficient than the monovalent form – not a surprise considering a
central idea of supramolecular chemistry is that polyvalency is
superior to monovalency in terms of both efficiency and affinity of
binding.[30]
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1.4.1 Self Assembled Multivalency (SAMul)
Barnard and Smith went on to define self-assembled multivalency
in a key review.[31] They defined the phenomenon as relying on
small molecules being self assembled into a larger nanostructure,
which has the ability to form a multivalent binding array. They
noted that this method has a variety of advantages including:
• spontaneous simple assembly,
• well-defined low-molecular-weight building blocks suitable
for clinical approval
• ability to assemble different active components into a single
nano-structure
• simple or triggered disassembly/degradation.[1, 31]
The advantages of these SAMul systems come about for a variety of
reasons. A carbon chain is often used as the hydrophobe to drive
self-assembly. The spontaneous assembly arises from a fine balance
between hydrophobic and hydrophilic components of the molecule.
Triggered bond cleavage of these systems is possible by inserting,
for example, an ester group between the hydrophobic tail and
hydrophilic binding group. Ester groups are well known to degrade
under biological conditions. When the ester undergoes hydrolysis,
the molecule breaks apart and self assembly of the system is no
longer possible. Once the molecule loses the ability to self assemble,
its binding ability is then "switched off".
Degradation and disassembly then also limits the biopersistance of
the molecule and helps with issues of toxicity that can be present
with polymeric multivalent binding systems.[29, 31]
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1.5 Potential Protamine Sulfate Mimics
A variety of different research groups have attempted to synthesise
a biologically compatible protamine sulfate mimic, and several
alternate approaches have been used. These include:
• cationic polymers and dendrimers
• protein based heparin binders
• small molecules
• Self-Assembled Multivalency (SAMul)
1.5.1 Cationic Polymers and Dendrimers
A popular approach for developing synthetic protamine sulfate
mimics is to base the structure on a large cationic compound which
binds heparin via multiple electrostatic interactions. Both
multivalent cationic polymers and dendrimers (branched
macromolecules of regular, well defined structure) have been used,
and can achieve high binding affinity to heparin. However, cationic
polymers tend to be biopersistant and hence toxic – this can be a
problem.[29, 31] It has been shown by Fréchet et al. that neutral, low
generation dendrimers are water soluble, and likely to be more
suitable for medical applications.[32]
NH2
HCl
FIGURE 1.4: Structure of Poly(allylamine hydrochlo-
ride)
Functionalised poly(allylamine hydrochloride) (PAH) derivatives
have been trialled as potential protamine sulfate mimics. Naturally
derived polymers have issues with batch-to-batch variation, and
hence, it was argued that a synthetic polymer is more appealing.[33]
Kamin´ski et al. chose to use a poly(allylamine hydrochloride)
backbone as it already finds a variety of uses within medicine and
therefore, it was possible that a functionalised derivative of this
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would also be biologically compatible. The scaffold was then
functionalised with arginine groups, to enable it to bind heparin in
the same manner as protamine sulfate. Azure A displacement
assays showed that the dose of this arginine-functionalised PAH
derivative required to neutralise a 1 mg dose of heparin was less
than half that of protamine sulfate (0.46 mg).[33] Cytotoxicity studies
were also performed and showed that the functionalised PAH
derivative was less cytotoxic than the PAH scaffold alone.
O O
NH2
OH
HO
O
O
HO NH2
OH
O O
OH
NH
CH3O
O
O
O
HO
HO
HO O
OH
OHHOO O
FIGURE 1.5: Top: structure of dextran.
Bottom: structure of chitosan.
Kamin´ski et al. also developed cationic derivatives of chitosan and
dextran. In vitro and in vivo testing of these compounds was
positive.[33] Notably, no immunogenic response was shown, and
they act as effective heparin antidotes. However, in rat models, it
has been shown that these compounds are not completely free of
side effects. The chitosan derivatives interact with erythrocytes
while dextran derivatives cause hypotension - like protamine
sulfate.[33]
Dex40-GTMAC3 is a functionalised dextran derivative with an
average molecular weight of 40 kDa, and functionalised with
glycidyltrimethylammonium chloride (GTMAC) at a ratio of 0.65
GTMAC groups per glucose unit.[34] Recently published work
shows that these functionalised dextrans are non-toxic,
biodegradeable and function well as protamine sulfate mimics.[35]
Toxicology studies on rats have shown that there is rapid renal
clearance of the drug, with plasma concentration falling to less than
half of that administered after 10 minutes, and little in terms of
tissue accumulation.[35] Therefore, this dextran derivative is much
better tolerated than protamine sulfate. However, the researchers
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are aware much more testing needs to be done before this
functionalised dextran derivative can enter clinical trials.
1.5.2 Proteins, Peptides and Peptoids
Ford, Hamza and Rabenstein used N-substituted glycine peptoids,
generated systematically by solid-phase synthesis.[36] The use of
substiuted peptoids (Figure 1.6) rather than peptides, leads to
several advantages, particularly when considering the use of these
molecules as potential drug candidates. Peptoids are resistant to
proteases unlike peptides and are better able to pass through
biological membranes. Most importantly as potential protamine
sulfate mimics, they do not trigger an immunogenic response.
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FIGURE 1.6: Generic tetrapeptide (top) and generic
tetrapeptoid (bottom). Adapted from [36]
It was discovered by Carson and coworkers that there is a naturally
occurring heparin interacting protein (HIP) present in human
uterine epithelial cells, and subsequently the heparin binding
domain of this protein was sequenced.[37, 38] In 2006, two synthetic
analogues (Figure 1.7) of this heparin interacting protein were
synthesised by Wang and Rabenstein.[39]
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FIGURE 1.7: Structure of HIPAP. Adapted from [39].
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These heparin interacting protein analogue peptides (HIPAP)
differed from each other only in the chirality of the amino acids that
were used. One used purely the endogenous L-form, and the other,
purely D-forms of the amino acids. It was noted that both L-HIPAP
and D-HIPAP are capable of binding heparin, neutralising its
anticoagulant activity, and that they are equally effective. It was also
shown that the spatial arrangement of the six lysines and the one
arginine residue play an important role in the heparin binding
ability, as a scrambled version of this peptide did not effectively
bind heparin. These observations suggest that charge density and
spacial organisation of charge, not chirality, are the most dominant
forces in these heparin-binding systems.
1.5.3 Small Molecule-Based Heparin Binders
There have been several small molecule based heparin binders
reported in the literature. Key examples include delparantag,
ciparantag and functionalised calix[8]arenes.[1]
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FIGURE 1.8: Structure of Delparantag. Adapted from
[40].
Delparantag (PMX-60056) is a novel salicylamide-derived small
molecule with a molecular weight of 1,126 Da.[40] It was designed to
interact with the pentasaccharide sequence and prevent the
interaction with antithrombin III. It underwent several phase IB/II
trials and showed promising results, notably being one of the few
potential protamine sulfate mimics capable of full reversal of the
effects of both unfractionated heparin (UFH) and low molecular
weight heparins (LMWH).[40, 41] However, the trial was halted and
14
then terminated in May 2012 due to participants developing
hypotension on administration of Delparantag.[42] No further trials
are currently in progress.
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FIGURE 1.9: Structure of ciraparantag.
Ciraparantag (PER977) (Figure 1.9) is another synthetic, water
soluble cationic molecule designed specifically to bind to both
LMWH and UFH by non-covalent hydrogen bonding and
electrostatic interactions.[43] It is currently undergoing phase II trials,
and if shown to be both safe and effective, it could become the first
broad-spectrum rescue agent for novel oral anticoagulants (NOAC).
It has already been shown that ciraparantag restores baseline
haemostasis within 30 minutes of administration, is well tolerated
by patients, and does not interact with several other drugs.[43, 44] The
interaction of ciraparantag was assessed with the anticonvulsives
lamotrigine and carbamazepine (the latter also finding itself used as
a mood stabiliser in bipolar disorder), and several cardiac
medications including the antiplatelet drug clopidogrel, which is
useful in the case of patients undergoing polypharmacotherapy.[7, 45]
Functionalised calix[8]arenes were reported by Cunsolo et al. in 2006
as potential protamine sulfate mimics. The calix[8]arene scaffold
(Figure 1.10) was chosen due to its conformational adaptability. Two
different functionalised calix[8]arene scaffolds were synthesised in
order to probe the effect of charge density on the binding affinity
towards heparin. It was also hypothesised by the researchers that
the flexibility of both the calix[8]arene and heparin would improve
binding affinity. On comparison of the results for binding heparin to
protamine sulfate, this was shown to be true, as the rigid structure
of protamine negatively affected the rate of complexation.[46]
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FIGURE 1.10: Structure of the functionalised
calix[8]arene synthesised by Cunsolo et al. Adapted
from [46].
It was also shown that the rate of complexation is affected more
strongly by the adaptability and flexibility of the host:guest
complex, than by simple charge density.
1.5.4 Self-Assembled Multivalency (SAMul)
Self-assembled multivalency (SAMul) has also been employed as a
method by which novel protamine sulfate mimics could be
produced. This approach is very different to that used by Ford and
Rabenstein, and has a variety of advantages which have already
been outlined above. Particularly useful is the ability to combine
several components into a single structure, and the possibility for
simple or triggered disassembly.
The use of SAMul in the development of nanoscale self-assembling
heparin binders was first reported in the literature by
Campo-Rodrigo, Barnard et al. in 2011.[29] This paper showed that a
self-assembling dendron (Figure 1.11) could be used to bind heparin
when functionalised with amines, that are protonated at
physiological pH, and a hydrophobic group is necessary to drive
the self-assembly. This implies that at least part of binding the
self-assembled nanoscale interface to heparin has an electrostatic
component. However, it was also noticed by the researchers that the
synthesis of this system was certainly not facile, and that significant
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further work was necessary to probe the ability of this dendron to
disassemble and degrade, as it was already known that dendrimers
are biopersistent and can be toxic.
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FIGURE 1.11: Structure of the C22-G1 self-assembling
dendron synthesised by Campo-Rodrigo et al.
Adapted from [29].
Further work was carried out on this system by Bromfield et al. to
probe whether this self-assembling "pseudo-dendrimer" was still as
effective at binding heparin in biologically competitive media.[47]
The binding assays in the Campo-Rodrigo paper were only
performed in phosphate buffered saline (PBS), which bears little
resemblance to human serum in terms of the electrolytes that it
contains. Therefore, the assays to assess heparin binding were
performed in a solution of 150 mM NaCl and 10 mM Tris-HCl. It
was shown that C22-G1 still self-assembles in solution, and the
increased salt concentration increases the size of the self-assembled
micelle. This is unsurprising as increasing the ionic strength of a
solution is known to increase both the screening of surface charge
and the impact of the hydrophobic effect.[47] This then leads to a
greater number of individual molecules being included in the
self-assembled micelle, hence increasing its diameter.
Bromfield then went on to assess the self-assembly of C22-G1 in
human serum. Human serum contains all the electrolytes and blood
components found within human blood, with the exception of those
involved in blood clotting.[47] It was hoped that if this system could
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still function in human serum, and be a more effective heparin
binder than the currently utilised protamine sulfate, then medical
application of these self-assembling pseudo-dendrimers could
become reality. Unfortunately, the results showed that C22-G1
becomes less effective as a heparin sulfate binder in human serum,
with its CE50 value rising from 0.28 to 0.96. However, the compound
was demonstrated in some clotting assays to still function optimally
in human plasma.[47]
The effect of flexibility on binding self-assembling nanoscale
interfaces to heparin and/or DNA, was then studied. Fechner,
Albanyan et al. modified only the binding group and kept the
hydrophobic component of their systems the same.[48] This work
showed that certain binding groups had a greater binding affinity to
heparin/ DNA than others (Figure 1.12).
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FIGURE 1.12: The differences in structure between
spermidine (above) and spermine (below). From [48].
The self-assembling interfaces with spermidine ligands had a
greater affinity for heparin, whilst those with spermine ligands had
greater affinity for DNA. It was also noted that DNA appears to be a
“shape-persistent” polyanion, which will attempt to organise the
SAMul assembly that it is presented with. In contrast, Heparin is a
“adaptive” polyanion, which changes itself in response to the
SAMul binding surface.[48] These results also strongly agree with the
arguments made by Cunsolo et al. that the flexibility of heparin also
plays a key role in binding.[46]
Over the past 6 years, the structure of these self-assembling
nanoscale heparin binders has been repeatedly modified, and is
now very different to the structure originally used by
Campo-Rodrigo and Barnard.[29] It is no longer a first generation
dendron, but a small, discrete molecule capable of self assembly.
These molecules now consist of a hydrophobic carbon chain, used
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to encourage the molecule to self-assemble in aqueous media, and a
binding group displayed on the outside of the self-assembled
micelle, which is positively charged at physiological pH.
More recently, work has been published exploring the effect of
modifying the hydrophobic carbon chain on binding of these
nanoscale systems to both heparin and DNA. Vieira, Liljeström et al.
used C14-DAPMA, C16-DAPMA and C18-DAPMA to assess the
effect of changing hydrophobic chain length on binding to heparin
sulfate.[49] It was noted that altering hydrophobic chain length had
an effect on the solubility of these nanostructures, as C18-DAPMA
was poorly soluble in PBS buffer. The measured ζ- potentials also
highlighted the effect changing the length of the carbon chain has
on the ability of the molecule to self-assemble. The greater the
ζ-potential, the greater the driving force required for self assembly,
and this is seen to increase with increasing chain length. Albanyan,
Laurini et al. also modified the hydrophobic chain by changing the
number of double bonds along its length.[50] The self-assembly of
these structures was quantified using Nile Red assays, and it was
shown that increasing numbers of double bonds increased both
critical micelle concentration, as well as the diameter of the
self-assembled micelles. Surprisingly, results also showed that
altering the number of double bonds in the carbon chain alters the
selectivity of these systems towards both DNA and heparin. C18-1
shows a strong preference towards heparin binding relative to that
for DNA, whilst the results are the reverse for C18-3. This is
believed to occur because of the degree of preorganisation imparted
into the molecule by increasing numbers of cis double bonds and
the "shape-persistant" behaviour of DNA.
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FIGURE 1.13: The self-assembling nanoscale binder
developed by Chan et al. From [51].
Finally, it has been noted that these newer self-assembling nanoscale
binders can also display chiral selectivity (Figure 1.13). It is known
that a SAMul binder composed of only palmitic acid and a
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L/D-lysine binding group will bind to heparin and DNA, but
display no chiral preference.[51] On insertion of an amino acid spacer
group, in this case glycine, chiral selectivity was "switched on". This
chiral selectivity is useful as it enables us to tune the selectivity of
the SAMul interface towards a particular biological polyanion.
Binding assays show that C16-Gly-D-Lys has a much improved
affinity for DNA compared to its analogous L-lysine containing
counterpart, and it was suggested that the insertion of the glycine
spacer group enables the molecule to "better express its chirality", as
the insertion of the glycine spacer group modifies both the shape
and polarity.[51] It was also suggested that the addition of a glycine
spacer leads to additional hydrogen bonding sites and potentially
modifies the binding between the SAMul system and binding
partner. As a consequence, it is believed that this chiral selectivity
may remain, if the spacer group is changed from glycine to another
chiral amino acid.
Using self-assembly to create systems capable of inhibiting the
function of heparin sulfate has not only been explored by Smith and
coworkers. In 2014, DeGrado et al. published a paper in which the
phenomenon of self-assembly was applied to create
heparin-binding foldamers.[52] Foldamers are non-biological
sequence specific polymers of a defined length, which also possess
well defined secondary and tertiary structures. They are often used
to assess the folding and function of various biomacromolecules
and have been used more recently to inhibit protein-protein
interactions. The foldamers used by DeGrado et al. were based on a
repeating pattern of lysine and 5-amino-2-methoxy-benzoic acid
(Sal) units (Figure 1.14).
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FIGURE 1.14: Repeating Lys-Sal unit in the heparin-
binding foldamers used by DeGrado et al. From [52].
The results showed that the binding affinity of these Lys-Sal
foldamers did not depend on the chirality of the lysine side chains,
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and that like the nanoscale SAMul systems developed by Chan et
al., self-assembly of the foldamer is necessary before heparin
binding can take place.[51, 52]
1.6 Designing Novel Nanostructures
The novel molecules in this work (Figure 1.15) were designed in
such a way that they have low molecular weight - as it is known
these are more likely to achieve approval for medicinal use.[1] The
lysine binding group has been chosen due to its ubiquitous
appearance in nature, particularly within polyanionic binding
proteins, and for its ability to bind heparin, as the amino acid is
positively charged at physiologically relevant pH.[53]
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FIGURE 1.15: The novel self-assembling heparin
binders synthesised in this work.
L-R Top row: C16-L-Ala-L-Lys, C16-L-Ala-D-Lys. Bot-
tom row: C16-D-Lys-L-Ala, C16-D-Ala-D-Lys
The use of the alanine spacer here is an extension of previous work
by Chan et al.[51] The original work used a glycine amino acid as a
spacer group between the C16 carbon chain and the lysine binding
group. It was this spacer group which appeared to give this
self-assembled interface chiral selectivity towards DNA, with the
effect being less pronounced on binding to heparin sulfate. It was
hypothesised by the researchers that the difference in chiral
selectivity is perhaps due to the more polydisperse nature of
heparin. Glycine is unique in the sense it is the only achiral
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naturally occurring amino acid. By changing the glycine spacer to
an alanine residue, we hoped to elucidate whether the chirality of
the spacer group also has any effect on the binding to heparin
and/or DNA.
The inclusion of the carbon chain as a hydrophobic group drives the
self assembly of these nanoscale compounds, due to the
hydrophobic effect.[29] It is known from previous work by Vieira,
Albanyan et al. that there is a fine balance between the size of the
hydrophobic and hydrophilic components of the molecule.[49] If the
balance is tipped too far in either direction, the molecule either does
not self-assemble as the hydrophobic carbon chain is not large
enough to drive the self-assembly, or the nanoscale interface is
poorly soluble in aqueous media and hence unsuitable for its
desired purpose. For this reason, a C16 carbon chain was chosen as
the hydrophobic component for this family of nanoscale heparin
binders, as we reason it is sufficiently hydrophobic to drive
self-assembly, without adversely affecting the molecule’s solubility
in aqueous media.
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1.7 Project Aims
As a result of the issues outlined above, it would be clinically useful
if we could develop systems to do two things:
1. to develop another rescue agent with a favourable
toxicological and pharmacokinetic profile to replace
protamine sulfate, or to develop a rescue agent which binds
only to the active parts of heparin.
2. to develop a non-viral vector agent which binds DNA, and
possesses a greater potency than those already in existence.
The work herein attempts to approach these issues and synthesise a
potential protamine sulfate mimic, or a new non-viral vector
suitable for gene therapy.
In order to achieve this however, it is necessary to understand in
more detail the binding interface between heparin sulfate and
synthetic nanoscale systems. In particular, we are interested in the
importance of chirality in mediating specific binding between
heparin sulfate or DNA and these synthetic systems. With this in
mind, the aims of this project are therefore as follows:
• To synthesise a family of related palmitic acid based
molecules, with a variety of chiralities - two pairs of
enantiomers which have a diastereomeric relationship with
each other (Figure 1.15).
• To characterise these molecules using 13C,1H NMR and
DEPT-135, alongside Mass Spectrometry and Infrared
Spectroscopy to prove the expected compounds have been
synthesised.
• To assess the degree of self-assembly of these molecules using
TEM, DLS and Nile Red competition assays.
• To assess the DNA binding ability of these novel molecules
using Ethidium Bromide competition assays.
• To assess the heparin binding ability of these potential
protamine sulfate mimics using a Mallard Blue assay.
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We hope to explore whether the enantiomeric selectivity between
heparin and DNA demonstrated previously by Chan and Bromfield
is a general outcome of inserting any amino acid between the C16
carbon chain and the lysine binding group.[51, 53] If this is the case,
we can then tune the binding of the lysine group to preferentially
bind the biological polyanions of our choosing. This would
demonstrate that the design of synthetic systems with greater
selectivity, and potentially fewer side effects than protamine sulfate
is possible.
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Chapter 2
Results and Discussion
2.1 Synthesis of Novel Nanostructures
2.1.1 Modification of Synthetic Route
The synthesis of the target compounds is outlined in Figure 2.1. It
employs a series of Boc-protection, TBTU-mediated peptide
coupling and Boc-deprotection steps. All target compounds were
characterised by 1H, 13C and DEPT-135 NMR, as well as MS and IR,
as outlined in the experimental (Chapter 5).
The original protocol for the synthesis of C16-Gly-D/L-Lys family of
nanoscale heparin binders originally published by Chan, Laurini et
al., was found to not work well for the synthesis of this new family
of heparin binders after the glycine group was replaced by
alanine.[51] In the coupling step to join the amino acid to the C16
carbon chain, as shown in Figure 2.1, the original method has the
reactants being dissolved in dichloromethane (DCM), but on
removing solvent in vacuo, the residue is redissolved into ethyl
acetate, before washing the organic layer. The paper gives an
observed yield of 40% for both enantiomers. In comparison, using
this method for the synthesis of C16-Ala(Boc) this observed yield
falls to only 22%.
After discussion with coworkers, it was decided to change the
solvent for this washing step from ethyl acetate to DCM. Modifying
the solvent used here caused the yield to rise dramatically (L: 51 %;
D: 68 %), giving a much more substantial amount of product after
this step and thus permitting further synthesis at scale.
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On searching the literature, it was discovered that this behaviour is
already known i.e. changing the amino acid changes the solubility
of a compound in a given solvent. According to Needham et al.,
glycine as an amino acid is much more soluble than alanine in all of
the solvent systems that were tested.[54] Therefore, the effect that
changing the solvent had on yield is not surprising, and shows that
the original issue with the low yield was due to the C16-Ala(Boc) not
being sufficiently soluble in the solvent and instead forming a
suspension. It is then likely that some of the product was lost when
the layers were separated after the addition of NaHSO4.
From previous work by Smith and coworkers, it is well known that
small changes in these systems cause dramatic changes in their
properties and behaviour. Chan reported that inserting a glycine
spacer between the lysine binding group and carbon chain
introduced chiral selectivity towards both heparin and DNA, whilst
Vieira noted that changing the length of the hydrophobic carbon
chain altered the solubility in aqueous media and also affects their
ability to self-assemble, finally Albanyan stated that the inclusion of
alkene groups within the hydrophobic carbon chain influences the
size of the SAMul nanostructures.[49–51]
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FIGURE 2.1: Modified synthetic route used to synthe-
sise the novel heparin binding nanostructures
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2.1.2 TBTU-Mediated Peptide Coupling
The synthetic route shown in Figure 2.1 employs a sequence of Boc
protection and deprotection steps. This is achieved by the use of Boc
anhydride (di-tert-butyldicarbonate), to introduce the Boc
protecting group onto the amine moiety. This technique is used to
confer regioselectivity onto the TBTU-mediated peptide coupling
steps, the mechanism of which is shown in Figure 2.2, by blocking
the reactive amine, and preventing self-polymerisation of the amino
acid. This forces the reaction to take place by first removing a
proton from the carboxylic acid group, and further reaction with
TBTU activates the carboxylic acid derivative.[55] The activated
carboxylic acid derivative then reacts with the amine group of the
other reagent, in this case C16-Ala.
2.1.3 Hygroscopic Properties of Lysine
Whilst carrying out the synthesis of the products outlined above, it
was noticed that some of the products appeared to be hygroscopic
and others were not. The property that the hygroscopic products
had in common is that they all contain a lysine group.
Consequently, C16-D-Ala-D-Lys and L-Lys(Boc)2 are hygroscopic,
whilst C16-D-Ala(Boc) is not. The lysine group introduces this
property because lysine is a significantly more polar amino acid.
It is known that charged compounds make stable hydrates when
exposed to water, hence the affinity of the lysine group for water
within the atmosphere and the hygroscopic behaviour that has been
seen. Reaction conditions have not been changed because of this
behaviour, but it does cause issues with handling these products, as
they absorb water rapidly on being exposed to air. Consequently,
they are stored under a nitrogen atmosphere, with lids wrapped
tightly in parafilm before being frozen.
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2.1.4 Adding and Removing Boc-Protecting Groups
Boc protecting groups are used in this synthesis to generate
regioselectivity in the reaction, which then results in only one
isomer of product being formed. This has been achieved using Boc
anhydride and sodium hydroxide as the base. The mechanism for
this is shown in Figure 2.3.
O O
O
O
O
HO
O
NH
H
NH2
- O
-CO2
H2N
OHO
N
O
O
H H
NaOH
H2N
OHO
H
N
O
O
FIGURE 2.3: Mechanism for Boc protection of L-Ala.
Only Boc- protection for one of the NH2 groups is
shown.
Once the reaction is complete and the desired product has been
formed, the protecting groups are no longer useful and need to be
removed. There are a variety of ways in which this can be done, but
for Boc-deprotection, this reaction is always acid mediated (Figure
2.4).
30
H
N
O
O
OHO
H2N
ClH
H
N
O
O
OHO
H2N
H
N
O
O
OHO
H2N
H
NH2
OHO
H2N
H
H
H2
N
O
O
OHO
H2N
CO2+
+
FIGURE 2.4: Mechanism for Boc-deprotection of L-
Ala(Boc). Only Boc-deprotection for one NH2 group
is shown.From [56]
In this work, both dissolving the Boc-protected product in solvent
(usually DCM or MeOH), then bubbling HCl gas through the
solvent, and dissolving the Boc-protected product into 15 eq. 4 M
HCl in dioxane have been used.1
Figures 2.5 and 2.6 show the effect of dissolving the Boc-protected
product 4 M HCl in dioxane, then stirring the solution for one hour.
Both of these techniques are successful at removing the Boc
protecting group - with loss of the 1H NMR peak at 1.45 ppm, which
corresponds to the Boc group.
1This change is not due to the compounds, but purely due to a limited supply of
HCl gas. The author however does have a preference for using 4M HCl in dioxane
as this appears to be easier to use.
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FIGURE 2.6: 1H NMR of C16-L-Ala after removal of
Boc-protecting group using 4 M HCl in dioxane
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2.1.5 NMR Analysis of Target Compounds
The four target compounds - C16-L-Ala-L-Lys, C16-L-Ala-D-Lys,
C16-D-Ala-L-Lys and C16-D-Ala-D-Lys have all been successfully
synthesised. These constitute two enantiomeric pairs of binders
which have a diastereomeric relationship to each other. The 1H
NMR spectra are presented in Figures 2.7 to 2.10.
These NMR spectra are broadly similar to each other; as would be
expected. Key proton resonances all appear at equivalent ppm
values (Table 2.1). However, it is clear that the coupling patterns of
the CH2-N protons are somewhat more complex for the homochiral
pair (L,L/D,D) in comparison to the heterochiral pair (L,D/D,L).
which is most apparent for the resonances at ca. 3.1 ppm. This
reflects the diastereomeric relationship of these two pairs of
compounds, leading to differences in coupling, possibly induced by
conformational differences between the molecules, leading to
subsequent change in torsion angle between coupled protons.
TABLE 2.1: A summary of the differences of chemical
shift in 1H NMR, between the four target compounds
Compound Name Ala (CH) δ Lys (CH) δ CH2-j δ CH2-b δ
C16-L-Ala-L-Lys 4.31 3.91 3.12 2.97
C16-D-Ala-D-Lys 4.29 3.90 3.15 2.95
C16-D-Ala-L-Lys 4.32 3.92 3.17 2.95
C16-L-Ala-D-Lys 4.32 3.92 3.17 2.97
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TABLE 2.2: A summary of the differences of chemical
shift in 13C NMR, between the four target compounds
Compound Name Ala (CH) δ Lys (CH) δ CH2-NH δ CH2-NH2 δ
C16-L-Ala-L-Lys 50.81 54.04 40.37 33.21
C16-D-Ala-D-Lys 50.80 54.02 40.59 33.22
C16-D-Ala-L-Lys 50.90 54.35 40.44 33.22
C16-L-Ala-D-Lys 50.92 54.36 40.65 33.21
As with the results obtained from 1H NMR, the results from 13C
NMR are broadly equivalent to each other, with key resonances
appearing at equivalent ppm values. The 13C NMR spectra are
presented in Figures 2.11 to 2.14. However, in this case, the
resonances of the carbon atoms at the chiral centres within these
molecules varies much more significantly. This difference in 13C
NMR highlights the differences between the two diastereotopic
pairs of binders that have been synthesised in this work. This
further supports the hypothesis posed earlier that the two pairs of
molecules adopt differing conformational arrangements in solution.
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FIGURE 2.11: 13C NMR of C16-L-Ala-L-Lys
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FIGURE 2.12: 13C NMR of C16-D-Ala-D-Lys
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FIGURE 2.13: 13C NMR of C16-D-Ala-L-Lys
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FIGURE 2.14: 13C NMR of C16-L-Ala-D-Lys
2.1.6 Compounds synthesised
From the compounds that have been synthesised in this work,
several insights have been obtained.
1. The protocol for the synthesis of the C16-Gly-L/D-Lys as
previously published by Chan et al. does not necessarily give
high yields for the synthesis of this new family of
self-assembling heparin binders.
2. Some of these products are hygroscopic, which leads to
difficulties in handling.
3. Both bubbling HCl gas through the solvent in which the
Boc-protected product has been dissolved, or by dissolving the
Boc-protected product in 4M HCl in dioxane will successfully
remove the Boc protecting group.
4. The relationships between these target molecules leads to
differences between them, which can be seen in both 1H and
13C NMR of these target compounds.
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TABLE 2.3: A summary of the compounds that have
been successfully synthesised
Compound name Yield Compound name Yield
L-Lys(Boc)2 43% D-Lys(Boc)2 88%
C16-L-Ala(Boc)2 51% C16-D-Ala(Boc)2 67%
C16-L-Ala 74% C16-D-Ala 98%
C16-L-Ala-L-Lys(Boc)2 88% C16-D-Ala-L-Lys(Boc)2 59%
C16-L-Ala-L-Lys 41% C16-D-Ala-L-Lys 82%
C16-L-Ala-D-Lys(Boc)2 86% C16-D-Ala-D-Lys(Boc)2 91%
C16-L-Ala-D-Lys 81% C16-D-Ala-D-Lys 95%
2.2 Assessing Self-Assembly
Several methods have been used to probe the self-assembly
behaviour of the novel binders that have been synthesised in this
work. These methods are:
• Nile Red Assay
• Dynamic Light Scattering (DLS)
• Transmission Electron Microscopy (TEM)
The theoretical background and results obtained from each of these
methods is discussed in detail below.
2.2.1 Nile Red Assay
The aggregation behaviour in solution of these novel heparin
binders can be probed by using Nile Red. Nile Red is a known
solvatochromic fluorophore, where a change in polarity of the
solvent alters the colour of the solution as well as influencing
fluorescence intensity.[57]
Nile Red is (unsurprisingly) red in polar solvents, such as ethanol
and undergoes a significant blue-shift in colour when exposed to
non-polar solvents. Importantly, it only fluoresces weakly in polar
solvents and strongly in non-polar solvents.[57]
These properties of Nile Red have been frequently used within the
literature. Plenderleith et al. used the colour changing properties of
the dye to probe the morphology in water of a highly branched
39
polymer chain at varying temperatures.[58] In polar environments,
i.e. in the open coil form of the polymer, the λmax of the solution was
660 nm. In the non-polar environment of the globular form, λmax fell
significantly.
Bongiovanni et al. exploited both the fluorogenic and
solvatochromic properties of the dye to map hydrophobic areas of
various biological structures - particularly amyloid aggregates
which are already known to play a role in a variety of
neurodegenerative disorders including Alzheimers disease.[59]
NH3C
H3C
N
O O
FIGURE 2.15: Structure of Nile Red
Nile Red is a known fluorophore, due to the extended conjugation
within the molecule (Figure 2.15). Nile Red has been used to assess
the self-assembly of surfaces in polar solvents. In the absence of
self-assembly, the fluorescence will be weak as the dye experiences
the polar solvent environment. However, once self-assembly occurs,
the Nile Red partitions into the non-polar, hydrophobic domain
often in the centre of the system and fluorescence intensity
increases. This behaviour then allows the Critical Aggregation
Concentration (CAC) to be assessed. A Nile Red Assay, therefore,
monitors the fluorescence of a solution of Nile Red in a polar
solvent in the presence of increasing amount of surfactant (in this
case, the novel SAMul binders), The concentration at which the
fluorescence intensity starts to increase can be taken as an
estimation of the CAC value.
40
01000
2000
3000
4000
5000
6000
0 0.5 1 1.5 2
In
te
ns
ity
 a
t 6
35
 n
m
 / 
a.
u
Log10 [C16-L-Ala-L-Lys]
FIGURE 2.16: Fluorescence intensity of Nile Red at 635
nm in the presence of increasing concentration of C16-
L-Ala-L-Lys in Tris-HCl buffer.
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FIGURE 2.17: Fluorescence intensity of Nile Red at 635
nm in the presence of increasing concentration of C16-
D-Ala-D-Lys in Tris-HCl buffer.
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FIGURE 2.18: Fluorescence intensity of Nile Red at 635
nm in the presence of increasing concentration of C16-
D-Ala-L-Lys in Tris-HCl buffer.
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FIGURE 2.19: Fluorescence intensity of Nile Red at 635
nm in the presence of increasing concentration of C16-
L-Ala-D-Lys in Tris-HCl buffer.
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If the novel heparin binders did not aggregate in Tris HCl, the
fluorescence intensity at 635 nm would remain unchanged, despite
changing the concentration of binder solution. From Figures
2.16-2.18, it can be seen that this is not the case. Once the
concentration of the binder solution reaches a particular
concentration, the intensity increases sharply. Therefore, the data set
can be split in two; a set where intensity remains almost unchanged,
and a data set where it increases sharply. The point where these two
data sets intersect, allows the critical aggregation concentration
(CAC) of the binder to be determined.
The CAC of each novel binder has been determined in this way and
displayed in Table 2.4. The errors are reported as standard deviation
and have been obtained by LINEST analysis.
TABLE 2.4: A summary of the Critical Aggregation
Concentrations of each compound.
Compound name CAC /µM
C16-L-Ala-L-Lys 50 ± 3
C16-D-Ala-D-Lys 44 ± 3
C16-L-Ala-D-Lys 166 ± 3
C16-D-Ala-L-Lys 155 ± 3
These results show that pleasingly, all four novel binders do
aggregate in Tris-HCl buffer solution. For C16-L-Ala-L-Lys, the CAC
was calculated as 50 µM ± 3 which is unsurprising when compared
to the values obtained by Chan and Vieira for C16-Gly-L-Lys (33 µM
± 3) and C16-DAPMA (38.5 µM ± 0.4) respectively.[49, 51] The
enantiomeric system, C16-D-Ala-D-Lys had, as expected, essentially
the same CAC value. However, the diastereomeric pair of
enantiomers C16-D-Ala-L-Lys, C16-L-Ala-D-Lys had a much larger
CAC. This was unexpected, but on reviewing the literature was
perhaps not surprising. As these results suggest that the two
diastereomeric pairs have very different propensities towards
self-assembly.
It has been reported by Bouteiller et al., that changing the
stereochemistry of one amide group of a
1,3,5-benzene-tricarboxamide derived from a valine dodecyl ester
43
(Figure 2.20), leads to a significant change in the shape of the
nanoscale assembly.[60]
NHO
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FIGURE 2.20: Left: BTA(S,S,R)-Val.
Right: BTA(S,S,S)Val. Adapted from [60].
BTA(S,S,R)-Val self-assembled into long, rod like structures, whilst
BTA(S,S,S)-Val only forms dimers. From spectroscopic analysis and
Molecular Dynamics calculations, it was noted that the dimeric
form of BTA(S,S,S)-Val was very stable due to a large number of
both inter- and intramolecular hydrogen bonds, but BTA(S,S,R)-Val
was less stable in this form, and at increasing concentration
assembled into rod-like structures.
It was then proposed that this difference in behaviour arises from
the chiral mismatch in the "arms" of the molecule leading to slightly
weaker hydrogen bonds, and enforcing geometrical constraints on
the structure.[60]
It should be noted that the difference between the diastereomeric
pairs is much greater than that between C16-Lys and C16-Gly-Lys
studied by Chan et al., where there was little change in CAC on
insertion of the glycine spacer group.[51] This shows that the
insertion of a chiral amino acid as the spacer group has a substantial
and dramatic effect on the overall assembly event.
Secondly, the fact a considerably higher concentration is required
for aggregation implies the self-assembled micelles if the
diastereomeric systems may have significant structural differences.
Further characterisation would be necessary to probe this in further
detail (see below).
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2.2.2 Dynamic Light Scattering
In Dynamic Light Scattering (DLS), the sample is irradiated with
light, and the light is scattered by the contents of the sample. This
backscattered light at 173° is then measured. The assumption is
made that the object which scatters light is spherical, therefore DLS
says very little about the shape of the self-assembled nanostructure.
The intensity distribution shows how much light is scattered by an
object of a particular size, this will inherently be a larger amount for
larger objects. The volume distribution shows how many objects of
a particular size are scattering the incident light. Hence, the volume
distribution more clearly shows the contents of the sample, in terms
of statistical probability.
Finally, the polydispersity index (PDI) can tell us useful information
about the sample. For a perfectly monodisperse solution, the PDI is
equal to 1.0. For these samples under test, the PDI is far away from
1 (generally 0.5-0.6), and hence shows the samples do not contain
just one type of assembly, but that different types of aggregates are
also present.
DLS measurements were taken of all four novel nanoscale binders
at three different concentrations (0.25 mg ml-1, 0.5 mg ml-1 and 1 mg
ml-1), all giving a concentration of binder well above the CAC, as
determined by Nile Red. The DLS measurements at 0.25 mg ml-1
and 1.0 mg ml-1 are in Appendix A.
Novel binders were dissolved in 10 mM Tris-HCl + 150 mM NaCl
solution, before being passed through a 0.45 µM filter to exclude
dust particles. All measurements were obtained from 5 runs, and
performed in triplicate. It should be noted that the millimolar
concentrations required for DLS, are well above the micromolar
concentrations required for anion binding described later in this
thesis.
45
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FIGURE 2.21: Intensity distribution of a 0.5 mg ml-1
sample of C16-L-Ala-L-Lys
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FIGURE 2.22: Volume distribution of a 0.5 mg ml-1
sample of C16-L-Ala-L-Lys
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FIGURE 2.23: Intensity distribution of a 0.5 mg ml-1
sample of C16-D-Ala-D-Lys
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FIGURE 2.24: Volume distribution of a 0.5 mg ml-1
sample of C16-D-Ala-D-Lys
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FIGURE 2.25: Intensity distribution of a 0.5 mg ml-1
sample of C16-D-Ala-L-Lys
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FIGURE 2.26: Volume distribution of a 0.5 mg ml-1
sample of C16-D-Ala-L-Lys
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FIGURE 2.28: Volume distribution of a 0.5 mg ml-1
sample of C16-L-Ala-D-Lys
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In general terms, the intensity distributions show two peaks, one at
smaller size (<10 nm) corresponding to micellar objects and another
at a significantly larger size (100-500 nm) corresponding to
aggregation. The volume distribution indicates that the dominant
species present are the smaller micellar type assemblies for all four
novel binders in this work. Table 2.5 collects together the diameters
of these objects as well as the observed zeta potentials.
TABLE 2.5: A summary of the data obtained by DLS
for each compound.
Compound name Concentration / mg ml-1 Z-Average / nm ζ-potential /mV
C16-L-Ala-L-Lys 0.5 45.44 ± 0.98 35.5 ± 3.3
C16-D-Ala-D-Lys 0.5 83.83 ± 2.16 39.2 ± 2.2
C16-L-Ala-D-Lys 0.5 150.9 ± 29.97 43.3 ± 0.6
C16-D-Ala-L-Lys 0.5 98.51 ± 3.78 46.8 ± 0.5
The systems which self-assembled more effectively (C16-L-Ala-L-Lys
and C16-D-Ala-D-Lys) broadly showed more reproducible DLS
traces, which supports the hypothesis that they form better-defined
aggregates in comparison to those formed by C16-D-Ala-L-Lys and
C16-L-Ala-D-Lys. In all cases,however, micelles (<10 nm) appear to
nevertheless be the most dominant form of assembly. It should also
be noted that some of these larger aggregates observed by DLS are
in part, an artifact of the assay being performed at millimolar
concentrations and do not fully reflect the micromolar
concentrations described later in this work for anion binding.
2.2.3 Zeta Potentials
ζ-potentials of all four novel binders were also obtained by DLS at a
concentration of 0.5 mg ml-1 using folded capilliary cells (DTS1070).
Errors are reported as standard deviations.
The ζ-potential is a measure of the electrostatic charge/ repulsion
between molecules. The greater the value of the ζ-potential, the
more charged the nanoscale interface.
It can be seen from Table 2.5 that all ζ-potentials are positive,
reflecting the protonation of the lysine binding group at
physiological pH. Also, there is slight variation between them.
C16-L-Ala-L-Lys and C16-D-Ala-D-Lys having very similar
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ζ-potentials to each other (within error) while C16-L-Ala-D-Lys and
C16-D-Ala-L-Lys have higher ζ-potentials of ca. 45 mV. If binding
were to depend solely on charge density, it might be expected that
C16-L-Ala-D-Lys and C16-D-Ala-L-Lys would perform more
effectively.[51] This increased ζ-potential for the C16-L-Ala-D-Lys and
C16-D-Ala-L-Lys pair could explain their propensity towards further
aggregation in comparison to C16-L-Ala-L-Lys and C16-D-Ala-D-Lys,
and thus explain why larger aggregates are observed by DLS for the
former pair of systems.
2.2.4 Transmission Electron Microscopy Analysis
Transmission Electron Microscopy was carried out with significant
help from Meg Stark at the University of York.
Transmission Electron Microscopy (TEM) uses electrons to image
objects on the nanoscale.[61] These electrons have a wavelength
much shorter than that of visible light, which is particularly useful
as it dramatically improves the limit of resolution in comparison to
an optical microscope and enables imaging across the entire
nanoscale size range. However, TEM is not without its
disadvantages. The high vacuum necessary for this technique can
sometimes damage delicate assembled structures and the high
electron beam energies can often damage the formvar grid itself,
leading to holes within the sample.
The samples for TEM were first dissolved into Milli-Q water before
being placed onto the formvar grid. The nanoscale assemblies were
then negatively stained using 1% uranyl acetate and left to dry for
30 minutes.
The binders were imaged at a concentration of (1 mg ml-1/ 2.27
mM). The images obtained from this concentration allows us to
visualise these novel nanoscale binders (Figure 2.29). The largest
objects in the TEM image for C16-L-Ala-D-Lys may well be
attributed to holes within the formvar grid, rather than larger
aggregates.
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FIGURE 2.29: TEM images of all four novel binders
imaged in the absence of a polyanion. Top left: C16-
L-Ala-L-Lys, Top right: C16-L-Ala-D-Lys. Bottom left:
C16-D-Ala-L-Lys, Bottom right: C16-D-Ala-D-Lys
The nanoscale assemblies present in these samples are
approximately 5 nm ± 1 in diameter. The micelles appear as lighter
coloured circular objects against the dark grey background of the
formvar grid, and in each case, in agreement with DLS, it is evident
that micelles <10 nm in diameter are being formed. Furthermore,
these micelles are evidently stable not only under the drying
conditions described earlier, but also under the electron beam.
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Clearly, there is some disagreement between the values obtained via
DLS and those from the TEM images above. This arises due to the
fact that the nanoscale assemblies are in solution for DLS and hence
the hydrodynamic diameter (i.e the nanoscale assembly and shell of
solvating water molecules) is measured, whilst TEM requires the
samples to be dried before they are imaged and therefore measures
only the size of the nanoscale assembly.
2.2.5 Circular Dichroism
The Circular Dichroism analysis of the compounds in this work has
been performed by Dr Andrew Leech at the University of York.
Circular Dichroism (CD) relies on plane polarised light, and its
absorbance by UV-active components of molecules. A CD signal
only results when the left and right handed components of plane
polarised light are absorbed to differing extents by a chiral
molecule.[62] An absorbance at 220 nm is indicative of the molecule
within the sample posessing a peptide bond.
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FIGURE 2.30: Comparison of C16-L-Ala-L-Lys and
C16-D-Ala-D-Lys binders by Circular Dichroism
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FIGURE 2.31: Comparison of C16-L-Ala-D-Lys and
C16-D-Ala-L-Lys binders by Circular Dichroism
Figures 2.30 and 2.31 show that two enantiomeric pairs of molecules
have successfully been synthesised as the CD spectra show the
molecules broadly absorb light in an equal, but opposite fashion.
It can also be said that there are significant differences between the
diastereomeric pairs e.g. C16-L-Ala-L-Lys and C16-L-Ala-D-Lys, in
terms of both absolute ellipticity and line shape. These differences
in CD support the hypothesis posed earlier, on analysis of 1H NMR,
that these diastereomeric pairs fold themselves in very different
ways and help explain why their propensity towards self-assembly
differs.
However, these CD spectra cannot be used alone to make any
suggestions about the way these molecules choose to fold within
solution.
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2.3 Polyanion Binding Studies
The ability of these systems to bind biological polyanions was then
explored. Of particular interest was the determination whether
differences in propensity towards self-assembly would also be
translated into differences in polyanion binding.
2.3.1 Ethidium Bromide Displacement Assay
Ethidium bromide (EthBr) is an intercalating agent commonly used
in molecular biology to stain nucleic acids for visualisation in gel
electrophoresis.The central structure of the molecule is a
phenanthridine group, which also appears in several other
intercalating dyes.[63] It is this fused ring system that gives EthBr the
property that is being exploited in this case.
N CH3
NH2
H2N
Br
FIGURE 2.32: Structure of Ethidium Bromide
[63]
For exactly the same reasons as Nile Red, EthBr is also a
fluorophore. On binding to DNA, EthBr fluoresces strongly, with
λmax at 595 nm. This is believed to occur as binding to DNA forces
the ethidium bromide to shed bound water molecules, which are
known to be successful at quenching fluorescence.[64] It is this
fluorescence that can be monitored as a competing binder is
introduced in solution. If this new binder binds DNA more strongly
than EthBr, then EthBr is displaced, and fluorescence intensity
decreases. However, some believe that this does not necessarily
show the displacement of EthBr by another ligand, but instead
suggests the formation of a ternary complex.[65] Nevertheless, this is
still an effective comparative method of assaying DNA binders.
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A solution of DNA and EthBr in Tris-HCl buffer is made and the
novel binder is titrated into it, with the quenching of fluorescence
(and hence the displacement of EthBr) being monitored. This allows
quantification of the DNA binding ability of each novel binder, and
is particularly useful for comparing similar molecules under
identical assay conditions.
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FIGURE 2.33: Comparison of C16-L-Ala-L-Lys and
C16-D-Ala-D-Lys in EthBr assay
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FIGURE 2.34: Comparison of C16-L-Ala-D-Lys and
C16-D-Ala-L-Lys binders in EthBr assay
Ethidium Bromide displacement assays were performed in
triplicate and errors are reported as standard deviations. From these
displacement assays (Table 2.6), it is possible to calculate EC50 and
CE50 values. EC50 is the effective concentration of binder necessary
to displace 50% of the dye, whilst CE50 is the charge excess of the
binder when 50% of the dye has been displaced.
TABLE 2.6: A summary of the data obtained from
Ethidium Bromide displacement assays.
Compound name EC50 (µM) CE50
C16-L-Ala-L-Lys 15.61 ± 2.14 7.8 ± 1.06
C16-D-Ala-D-Lys 9.47 ± 1.27 2.76 ± 0.36
C16-D-Ala-L-Lys 18.75 ± 1.15 9.37 ± 0.55
C16-L-Ala-D-Lys 6.08 ± 0.98 3.05 ± 0.48
The results show that all four novel nanostructures successfully
displace Ethidium Bromide and bind to DNA at micromolar
concentrations. The effective concentrations necessary to bind DNA
are all substantially lower than those reported for CAC by the Nile
Red assays performed previously. This shows that the presence of
DNA may assist self-assembly of the cationic compounds. It could
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be hypothesised that the negatively charged phosphate groups and
the positively charged lysine groups in the novel binders have
electrostatic interactions between them, and these interactions that
locates the binder close to the DNA. This then leads to a higher
concentration of the novel binder around the DNA strands,
encouraging self-assembly of the micelles and hence improving
binding.
The lower the value of CE50 the better the nanoscale interface is at
binding DNA and displacing EthBr. It can clearly be seen that there
is a very dramatic preference for D-Lys over L-Lys at the binding
interface, with the CE50 values for C16-D-Ala-D-Lys and
C16-L-Ala-D-Lys being 2.76 ± 0.36 and 3.05 ± 0.48 compared to 7.8
± 1.06 and 9.37 ± 0.55. These differences are well beyond the
established error range, and hence are considered to be significant.
It is remarkable that the enantiomeric systems are so different to one
another. Clearly, C16-D-Ala-D-Lys is a much better DNA binder
than C16-L-Ala-L-Lys, despite the fact they both self-assemble in
identical ways. The same argument can be made for the
C16-L-Ala-D-Lys and C16-D-Ala-L-Lys pair of compounds. This
clearly indicates that the chirality of the lysine is in full control of
the binding interface between these systems and DNA. As such, it
can confidently be asserted that lysine chirality controls DNA
binding affinity, and that both the chirality of the spacer group and
propensity towards self-assembly having very limited impact.
2.3.2 Mallard Blue Assay
Mallard Blue (MalB) is a arginine-functionalised thionine dye
developed by Bromfield et al., and it is used here in a competition
assay to quantify heparin binding.[66] It was noted that several
promising novel heparin sensors had been reported in the literature,
but they all arose through complex, multi-step synthesis which
made them difficult to prepare. It had been hoped that a
commerically available thionine dye could be used as a sensor to
quantify heparin levels, but no suitable candidate was
forthcoming.[67]
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FIGURE 2.35: Structure of the novel dye Mallard Blue
(MalB)
Instead, Bromfield and coworkers chose to design a novel heparin
binder (Figure 2.35). The thionine core was chosen due to its
fluorogenic & chromogenic properties, which would then allow the
heparin binding ability to be quantified. The idea to functionalise
this thionine core with arginine groups came from the observation
that protamine sulfate (which is heavily decorated with arginine
groups) functions in human serum and it was hoped that
appending these to the thionine core would give the new molecule
the ability to bind heparin in human serum and this binding to be
unaffected by other biologically relevant anions.[67] This was shown
to be true, and MalB not only binds heparin in competitive media,
the UV-Vis absorption is not peturbed by the presence of other,
structurally similar glycosoaminoglycans, but it also has a facile
two-step synthesis, which clearly gives this dye advantages over
those previously reported.[67, 68]
Like the EthBr assay, Mallard blue is also a displacement assay and
works as follows; the cuvette is charged with heparin sulfate and
Mallard Blue. A stock solution of binder is then titrated into this
cuvette and the Mallard Blue is displaced by the introduction of the
novel binder. This displacement of MalB causes both λmax to shift to
longer wavelength, and an increase in the absorbance at 615 nm, as
MalB functions as a "switch off" sensor for heparin. From this
change in the UV absorbance of the solution, EC50, CE50 and the
mass of binder necessary to neutralise a given dose of heparin
sulfate can all be obtained. The results are normalised against a
cuvette containing Mallard Blue in buffer, and a cuvette containing
both MalB and heparin. As a consequence of all licensed heparin
preparations in the EU being of porcine origin, all of the heparin
used in this displacement assay is also of porcine origin.[8]
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FIGURE 2.36: Binding Assay for C16-L-Ala-L-Lys and
C16-D-Ala-D-Lys
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Further normalisation has been applied to the results to account for
the turbidity of the samples at higher binding concentrations, which
resulted in the corrected absorbance rising above 1.0. (Figures 2.36
& 2.37).
Firstly, it can be seen that all four novel heparin binders give a
sigmoidal line shape in the Mallard Blue assay. At low
concentrations of binder, there is very little change in the
absorbance at 615 nm, as little MalB is displaced. Once a particular
concentration of novel binder is reached, the absorbance at 615 nm
increases sharply, this behaviour implies that self-assembly of the
novel nanoscale binders is necessary before heparin binding and
subsequent MalB displacement becomes possible. This is somewhat
different to what is observed in the EthBr assays.
Table 2.7 summarises the values of CE50, EC50, and the mass
necessary for each of the 4 novel binders to neutralise a given dose
of heparin. Errors are reported as standard deviations.
TABLE 2.7: A summary of the data obtained from Mal-
lard Blue displacement assay for the novel binders in
this work
Compound name CE50 EC50 (µM) Dose /mg 100 IU-1
C16-L-Ala-L-Lys 2.32 ± 0.08 125.5 ± 4.5 1.60 ± 0.05
C16-D-Ala-D-Lys 1.84 ± 0.36 110.3 ± 2.20 1.41 ± 0.02
C16-D-Ala-L-Lys 2.69 ± 0.22 145.2 ± 12.0 1.85 ± 0.15
C16-L-Ala-D-Lys 2.47 ± 0.12 134 ± 6.50 1.71 ± 0.08
Protamine Sulfate[47] 0.52 ± 0.05 2.34 ± 0.23 0.32± 0.02
The CE50 values obtained from the MalB assay (Table 2.7) show that
heparin binding behaves very differently to DNA binding. Broadly
speaking, the binding of C16-L-Ala-L-Lys and C16-D-Ala-D-similar.
This suggests that the chirality of the lysine binding group does not
drive the recognition event in this case. For C16-L-Ala-D-Lys and
C16-D-Ala-L-Lys, the former is somewhat better at binding heparin
sulfate and suggests that the chirality of the lysine group has some
influence in this case.
It can also be seen that the homochiral pair of binders posess a
higher affinity towards binding heparin than their heterochiral
counterparts, that have higher CE50 values. This reflects the
similarities in self-assembly behaviour previously shown by Nile
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Red assays. It could be hypothesised that there is some sort of
synergistic effect taking place, where the enhanced propensity
towards self-assembly of C16-L-Ala-L-Lys and C16-D-Ala-D-Lys
compared to C16-L-Ala-D-Lys and C16-D-Ala-L-Lys, enhances
heparin binding. This would also agree with the sigmoidal line
shape that is observed and that some degree of self-assembly is a
pre-requisite for heparin binding.
It is clear that the EC50 values are very different to the CAC’s
reported by the Nile Red assay. This implies that the binders under
test here behave differently when presented with heparin. The
CACs reported by Nile Red for the C16-L-Ala-L-Lys and
C16-D-Ala-D-Lys pair were 50 ± 3 and 44 ± 3, whilst the EC50 vales
reported here are 125 ± 2 and 110 ± 2 respectively. This indicates
that self-assembly is clearly necessary for effective multivalent
binding. Whilst the results obtained here show that the
C16-D-Ala-L-Lys and C16-L-Ala-D-Lys pair rely on heparin to some
extent to help encourage self-assembly, as the EC50 values here are
lower than the CACs obtained by Nile Red. This increased ability to
self-assemble is likely to occur due to the electrostatic interactions
between the negatively charged sulfate groups of heparin, and the
positively charged lysine residues of the novel binders. Smith and
co-workers have shown by several previous studies that both
charge density and flexibility of the host play a vital role in the
binding of heparin sulfate to protamine.[1, 48, 49, 51, 68, 69]
TABLE 2.8: A summary of the data obtained by Chan
et al. for their novel binders. From [51].
Compound name CE50 EC50 (µM)
C16-L-Lys 1.8 ± 0.1 100 ± 3
C16-D-Lys 1.8 ± 0.1 100± 3
C16-Gly-L-Lys 3.3 ± 0.3 180 ± 17
C16-Gly-D-Lys 2.3 ± 0.1 122 ± 2
It should be noted that the enantioselectivity of heparin binding
previously reported by Chan and Smith (Table 2.8), is still observed
here, specifically for C16-L-Ala-D-Lys and C16-D-Ala-L-Lys despite
changing the amino acid spacer group from the achiral glycine to
the chiral amino acid lysine. However, the enantioselectivity is not
observed for the diastereometic C16-L-Ala-L-Lys/ C16-D-Ala-D-Lys
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pair. This suggests that the precise mode of self-assembly (and
hence ligand display) plays a vital role in determining whether
enantioselective binding is observed at the nanoscale interface.
All 4 of the novel binders reported in Table 2.7 bind heparin sulfate
in Tris-HCl buffer. However, on comparison to the data obtained by
Bromfield et al. for the binding affinity of protamine sulfate to
heparin, none of the four binders synthesised in this work required
a lower dose to neutralise the effect of 100 IU of heparin, than
protamine sulfate did in these particular conditions.[47] This shows
that, unfortunately, these novel heparin binders are not more
effective in Tris-HCl buffer than protamine sulfate.
Finally, if the results for both the Ethidium Bromide and Mallard
Blue assays are considered together, it can be shown that the
flexibility of the host also plays a vital role in the binding of these
novel binders to a given biological polyanion. The lack of flexibility
in the structure of DNA leads to much greater stereoselectivity. It
has been noted by Fechner, Albanyan et al., that heparin sulfate is a
“adaptive” polyanion, i.e. it changes itself in response to the SAMul
binding surface it is presented with, whilst the opposite is true of
DNA and it will attempt to organise the SAMul interface, for this
reason it can be suggested that rigid DNA, with its well-defined
display of phosphate anions has a much greater enantio-preference
programmed into it.[48]
It is known from work by Vieira et al. that a large value for the
ζ-potential does not necessarily indicate that this is the best heparin
binder.[49] C16-D-Ala-L-Lys, is highly charged according to its
ζ-potential, but a poor heparin binder as determined by the MalB
assay. However, it was seen by Albanyan et al. that the greater the
ζ-potential for a given molecule, the greater the driving force for
self-assembly.[50]
2.3.3 TEM Analysis of Polyanion Binding
Since both Mallard Blue and Ethidium Bromide displacement
assays have been performed on these novel binders, it makes sense
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to also image these binders in the presence of both DNA and
heparin sulfate.
These images at x49000 magnification show how the presence of
DNA encourages the nanoscale micelles to self-assemble into larger
aggregates (Figure 2.38). The presence of unbound micelles is due to
the high concentration of binder within these samples.
Using the information obtained from the analysis presented
previously, it is known that the presence of DNA encourages the
binders to undergo self assembly at an effective concentration much
lower than the CAC, and that this concentration of binder solution
is known to encourage further self-assembly into larger aggregates.
Therefore, it can be said that the binders must form these large
aggregates that can be seen on the TEM images on binding DNA. A
further set of images at x120k magnification show these larger
aggregates even more clearly (Figure 2.39).
Excitingly, all 4 binders form aggregates much smaller than 150 nm,
Ghosh et al. determined that endocytosis is limited to objects under
150 nm in size. This suggests these Ala-Lys systems could be useful
DNA transfection agents.[17]
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FIGURE 2.38: TEM images of all four novel binders
imaged in the presence of DNA. x49000 magnification
Top left: C16-L-Ala-L-Lys, Top right: C16-L-Ala-D-Lys.
Bottom left: C16-D-Ala-L-Lys, Bottom right: C16-D-
Ala-D-Lys
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FIGURE 2.39: TEM images of all four novel binders
imaged in the presence of DNA. x120k magnification
Top left: C16-L-Ala-L-Lys, Top right: C16-L-Ala-D-Lys.
Bottom left: C16-D-Ala-L-Lys, Bottom right: C16-D-
Ala-D-Lys
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It is known from previous work that molecules which self-assemble
into spherical morphologies are the best heparin binders.[31] From
the images in Figure 2.40 it can be seen that all 4 novel binders do
form spherical aggregates, some of which clearly then undergo
further self-assembly to form larger, non-spherical assemblies. This
certainly mirrors the results obtained from the MalB assay, i.e. that
all 4 novel binders bind heparin at micromolar concentrations.
To some extent, the "beads on a string" phenomenon reported
previously by Campo-Rodrigo et al. for their self-assembling
dendrons capable of binding heparin can be seen in the TEM images
presented in Figures 2.40 & 2.41.[29] The phenomenon had been seen
repeatedly and reported several years earlier for the binding of
spherical cationic systems to DNA, and this hierarchical binding has
been fully characterised by Vieira et al., where it is viewed as being
anion-induced close packing of cationic spheres.[49, 70]. This
phenomenon helps explain why the results presented previously for
anion binding in Tables 2.6 & 2.7 state that more than one positive
charge on the binder is necessary to bind one negative charge from
either heparin sulfate or DNA. The TEM images presented in this
section show that not all of the positive charges on these nanoscale
assemblies are capable of binding directly to the biological
polyanion that they have been presented with.
In all cases, the TEM images look reasonably similar, suggesting
that differences in DNA and heparin binding cannot simply be
attributed to different morphologies of the self-assembled
nanosystems.
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FIGURE 2.40: TEM images of all four novel binders
imaged in the presence of heparin sulfate. x49000
magnification Top left: C16-L-Ala-L-Lys, Top right:
C16-L-Ala-D-Lys. Bottom left: C16-D-Ala-L-Lys, Bot-
tom right: C16-D-Ala-D-Lys
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FIGURE 2.41: TEM images of all four novel binders
imaged in the presence of heparin sulfate. x120k mag-
nification Top left: C16-L-Ala-L-Lys, Top right: C16-
L-Ala-D-Lys. Bottom left: C16-D-Ala-L-Lys, Bottom
right: C16-D-Ala-D-Lys
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Chapter 3
Summary and Conclusions
3.1 Synthesis of novel nanostructures
Two enantiomeric pairs of target compounds have been successfully
synthesised via a synthetic method developed in this work, and
their identity confirmed by 1H, 13C and DEPT-135 NMR, Mass
Spectrometry and Infrared Spectroscopy. It has been noted that
modifying the amino acid spacer group has a substantial effect on
the solubility of some intermediate products. This was unexpected,
but from previous work, it is not surprising that a small change in
the structure of these types of molecules leads to a large change in
their behaviour.[49, 50]
There are a variety of possible ways to remove the Boc-protecting
groups from these products. Both dissolving the Boc-protected
product in DCM before bubbling HCl gas through the solution and
dissolving the product in 4M HCl in dioxane have been used and
both successfully remove the protecting group, as shown by 1H
NMR.
1H NMR has also been used to show that there are subtle differences
between the four novel heparin binders in this work. Key proton
resonances all appear at equivalent ppm values. However, the
coupling patterns of the CH2-N protons differ between the two
diastereotopic pairs of compounds, allowing them to be
distinguished. Also proving that the chirality of the amino acid
building blocks does not get scrambled during synthesis, and
suggests that the diastereomers may have different conformational
preferences.
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3.2 Assessing Self-Assembly
3.2.1 Nile Red Assay
The Nile Red assays show that all four novel heparin binders
successfully aggregate in solution, and the calculated CAC values
for the C16-L-Ala-L-Lys, C16-D-Ala-D-Lys pair of molecules are
similar to those obtained by Vieira and Chan for C16-DAPMA and
C16-Gly-L-Lys respectively.[49, 51] It also shows that the insertion of
the chiral amino acid alanine does have an effect on the properties
of the overall nanoscale assembly, as the CAC value increases
significantly from 45 µM for C16-L-Ala-L-Lys/C16-D-Ala-D-Lys to
160 µM for the diastereomeric pair C16-D-Ala-L-Lys and
C16-L-Lys-D-Ala. This dramatic increase in CAC value was not
observed by Chan et al. on the insertion of the achiral amino acid
glysine into C16-Lys, but changing chirality leading to significant
changes in behaviour has been reported previously by Boutellier et
al. for a 1,3,5-benzene-tricarboxamide system.[51, 60] It suggests that
the conformational change observed by 1H NMR significantly
impacts on the ability of these compounds to self-assemble. It is
hypothesised that the head group becomes more sterically hindered
and less able to self-assemble effectively.
3.2.2 Dynamic Light Scattering
DLS can be used to obtain a large variety of information about a
sample, however, one of the main assumptions made by DLS is that
the objects which scatter light are spherical. Hence this analytical
method can say very little about the shape of the self-assembled
heparin binders in solution. Despite this, the polydispersity index
(PDI), Intensity and Volume distributions hold useful information.
The PDI of these samples is between 0.5 and 0.6, indicating that
these samples are not monodisperse (PDI = 1.0) and that a range of
different sized objects must be present within the sample. This
implies the presence of aggregates within the solution.
In general terms, the intensity distributions show two distinct
peaks; one at smaller size (<10 nm) that corresponds to the micellar
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objects, and a second at a substantially larger size (100-500 nm),
indicating the presence of aggregates within the sample. The
volume distribution indicates that the dominant species in each
sample are these smaller micellar-type assemblies.
It can also be seen that the systems which self-assemble more
effectively also broadly appear to posses more reproducible DLS
traces, which helps support the hypothesis that they form better
defined aggregates in comparison to those formed by
C16-D-Ala-L-Lys and C16-L-Ala-D-Lys. It should also be noted that
some of these larger aggregates that have been observed are an
artifact of the assay being performed at micromolar concentrations -
this higher concentration encourages further self-assembly.
3.2.3 Zeta potentials
The zeta potentials obtained for all four target compounds are
positive. This shows that the lysine binding groups on the
nanoscale interface are protonated at physiological pH.
C16-L-Ala-L-Lys and C16-D-Ala-D-Lys having very similar
ζ-potentials to each other (within error) while C16-L-Ala-D-Lys and
C16-D-Ala-L-Lys have higher ζ-potentials of ca. 45 mV. If binding
were to depend solely on charge density, it might be expected that
C16-L-Ala-D-Lys and C16-D-Ala-L-Lys would perform more
effectively.[51]
This increased ζ-potential for the C16-L-Ala-D-Lys and
C16-D-Ala-L-Lys pair could explain their propensity towards further
aggregation in comparison to C16-L-Ala-L-Lys and C16-D-Ala-D-Lys,
and thus explain why larger aggregates are observed by DLS for the
former pair of systems.
3.2.4 Transmission Electron Microscopy Analysis
Transmission Electron Microscopy was used to image the nanoscale
binders alone, and in the presence of both biological polyanions of
interest in this work. It can be shown by TEM that the nanoscale
binders undergo self-assembly, and the micelles have a diameter of
5 ± 1 nm. This is smaller than the diameter observed via DLS, this
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occurs because of the differing conditions in which the micelles are
sized. DLS measures the micelles in solution and therefore
determines hydrodynamic diameter, whilst TEM samples are dried
and hence only the nanoscale assembly itself is observed.
3.2.5 Circular Dichroism
Circular Dichroism shows that the four target compounds
synthesised in this work comprise of two enantiomeric pairs of
molecules, which absorb plane polarised light in a broadly equal
and opposite fashion.
It has also been noted that there are significant differences between
the CD spectra obtained for the diastereomeric pairs e.g.
C16-L-Ala-L-Lys and C16-L-Ala-D-Lys, in terms of both absolute
ellipticity and line shape. These differences in CD help support the
hypothesis that these diastereomeric pairs fold themselves in very
different ways and help explain why they possess differing
propensities towards self-assembly.
3.3 Polyanion Binding Studies
3.3.1 Ethidium Bromide Displacement Assay
The results from the Ethidium Bromide displacement assay show
that all four novel nanostructures do bind DNA and successfully
displace EthBr at micromolar concentrations. Again, this is much
lower than the CAC determined by Nile Red and implies that the
presence of DNA has an effect on binding the biological polyanion.
CE50 values show a dramatic preference for D-Lys as the binding
group over L-Lys. This suggests that the binding interface with
DNA is dominated by the precise interaction with the lysine binding
group, which is determined by chirality. The chirality of the alanine
spacer group, and the diastereomeric nature of the self-assembled
systems appear to have no effect on the recognition interface.
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3.3.2 Mallard Blue Assay
Mallard Blue assays have shown that if the target compounds are
unable to self-assemble, then their heparin binding ability is
"switched off". It can be stated that self-assembly of these
compounds is necessary before heparin binding and MalB
displacement is possible.
CE50 values show that the C16-L-Ala-L-Lys and C16-D-Ala-D-Lys
pair behave similarly to each other, and so too do C16-L-Ala-D-Lys
and C16-D-Ala-L-Lys. Furthermore, the former pair of binders do
appear to somewhat outperform the latter, and suggests that the
nature of the self-assembled system is much more dominant for
heparin binding. The EC50 values obtained by Mallard Blue assay
are different to the CACs. Therefore, it can be hypothesised that the
presence of heparin encourages self-assembly.
The chiral selectivity noted previously by Chan and Smith is still
present, to some extent as it is only observed for C16-L-Ala-D-Lys
and C16-D-Ala-L-Lys, but not the other two synthesised systems.
This suggests that this chiral selectivity is dependent on the precise
conformational orientation of the cationic surface ligands.
3.3.3 TEM Analysis of Polyanion Binding
In the presence of DNA or heparin, hierarchical aggregation of the
cationic micelles is observed by TEM. This hierarchical aggregation
has been understood as containing close packed cationic micelles
stabilised by the surrounding linear polyanions, as fully
characterised by Vieira et al.[49] The binder:DNA aggregates that are
observed when the binder is imaged in the presence of DNA, are
also small enough (< 150 nm in diameter) that they may
successfully undergo endocytosis into mammalian cells and hence
could potentially be useful DNA transfection agents.[17]
This phenomenon also provides more detail as to why the CE50
values indicate that more than one positive charge is necessary to
bind one negative charge on the polyanion. These images show that
not all of the positive charges on these nanoscale interfaces can be
arranged so that they can bind directly to the target.
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In summary, it is apparent that different systems herein are
optimised for heparin or DNA, revealing fundamental differences
in the way these polyanions bind to cationic targets. In general,
DNA appears to be more selective of the precise ligand it choses to
interact with - a consequence of its rigid, well-defined structure. In
contrast, heparin prefers the systems which has the greatest
propensity towards self-assembly, reflecting its adaptive,
polydisperse nature. However, for C16-L-Ala-D-Lys and
C16-D-Ala-L-Lys, which self-assembly poorly, some chiral ligand
preference is observed.
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Chapter 4
Further Work
Clearly there is much work to still be done with these
self-assembling nanoscale binders, before any would have a chance
of obtaining clinical approval.
Firstly, as one of the objectives for this work was to develop a viable
protamine sulfate mimic for clinical use and/or a non-viral gene
delivery method for genetic therapy, it is clear that the
biocompatibility of these nanoscale assemblies would need to be
determined. Previous work by Kim et al. has shown that
endogenous amino acids are more biologically compatible than
their exogenous analogues.[18] By extention, this supposes that the
C16-D-Ala-D-Lys system would be the least biologically compatible
nanoscale system that has been synthesised in this work. This is
unfortunate, as this system does bind particularly well to both
heparin sulfate and DNA. However, the use of D-amino acids does
offer the advantage of avoiding the breakdown by peptide enzymes
which can only work on the L-form.
The biocompatibility and cytotoxicity of these compounds can be
assessed by the agar diffusion assay.[71] However, it is also known
that this assay has several limitations, most importantly it shows
only the short term (acute) effects of the compound. If a drug affects
cell functionality without being cytotoxic, it will not be apparent in
this assay.[72]
Secondly, if any of these nanoscale binders are biologically
compatible, it would need to be seen if they still function in more
competitive media. This would first involve assessing the binding
of both heparin and DNA in human serum instead of the Tris-HCl
buffer that has been used previously, before proceeding to using
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human plasma. It is in these more competitive conditions where the
heparin binders synthesised by Bromfield et al. previously failed.[47]
Also, this system could be modified again to potentially tune the
system even further towards heparin and/or DNA. It would be
interesting to see the effect of modifying the alanine spacer group
by replacing it with a different amino acid. However, there is the
risk that this could be deleterous to the systems ability to
self-assemble if the spacer group is too highly charged.[48] From
previous results reported herein, it is unlikely to be wise to swap the
alanine spacer group to an amino acid containing a phenyl ring, as
this is likely to have a dramatic effect on the solubility of the
molecule. Further modifications also include changing the
hydrophobic component so that the CAC of the system is lowered,
and hence the self-assembled system would be more stable.
It has been shown in this work that the presence of either heparin
sulfate or DNA dramatically lowers the EC50 values to significantly
below the CAC as determined by Nile Red. Does this occur in the
presence of any other biological polyanions?
Molecular dynamics calculations could be performed on the novel
binders synthesised in this work to investigate whether the
hypothesis proposed by Boutellier et al. to explain the difference in
the shape of the self-assembled BTA-Val system on changing one
chiral centre, also holds for the L/D-Ala-L/D-Lys systems here.
These calculations could also explain why the systems synthesised
here containing the alanine spacer group, show an enhanced affinity
towards heparin sulfate and DNA, in comparison to those from
Chan and Smith. As yet, it has only been hypothesised that they are
"better able to express their chiral information at the self-assembled
interface".[51]
Finally, it would perhaps be useful to compare the DNA binding
affinity of the novel compounds in this work to that of commercially
available DNA transfection agents such as Lipofectamine,1 as well
as assessing whether these novel systems can indeed undergo
endocytosis into mammalian cells.
1This idea came from a discussion with Dr Christopher Serpell at the University
of Kent, for which I am grateful.
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Chapter 5
Experimental
5.1 General Materials and Methods
All reagents except novel compounds and Mallard Blue, were
obtained from commercial sources and used without further
purification unless otherwise stated. Mallard Blue was synthesised
by a previously reported synthesis.[66]
Thin layer chromatography (TLC) was performed on Merck
aluminium backed plates, coated with 0.25 nm silica gel 60.
Flash column chromatography was performed on silica gel 60 (35 –
70 µm) supplied by Fluka Ltd.
NMR spectra were recorded on a JEOL ECX400 (1H 400 MHz, 13C
100 MHz) spectrometer and assignments made through
corroboration with DEPT-135 spectra.
ESI and HR mass spectra were recorded on a Bruker Daltonics
MicroTOF mass spectrometer.
IR spectroscopy was performed on a Perkin Elmer Spectrum Two
FTIR spectrophotometer.
UV-Visible spectroscopy was performed on a Shimadzu UV-2401PC
spectrophotometer.
Fluorimetric assays (Nile Red, Ethidium Bromide) were performed
using a Hitachi F4500 fluorimeter.
Transmission Electron Microscopy was performed using a FEI
Tecnai 12 G2 electron microscope.
Dynamic Light Scattering was performed using a Malvern Zetasizer
NanoSeries machine.
Circular Dichroism was carried out on a Jasco J810 CD
Spectrophotometer (150w Xe lamp).
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Where both enantiomers of a compound has been synthesised,
synthesis of both enantiomers is identical to the L-enantiomer
unless otherwise stated. Where melting points of compounds are
not provided, this is due to insufficient compound remaining after
other analysis techniques have been performed.
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5.2 Synthesis of Novel Self-Assembling
Heparin Binders
Synthesis of L-Lysine(Boc)2 and D-Lysine(Boc)2
O
H
N
O
OH
O
HN
O
O
L-Lysine(Boc)2
C16H30N2O6
Molecular weight: 346.21
L-lysine (2.10 g, 14.36 mmol) and sodium hydroxide pellets (1.16 g,
29.00 mmol) were dissolved in deionised water (25 ml).
Di-tert-butyl dicarbonate (Boc anhydride) (6.25 g, 28.63 mmol) was
dissolved separately into 25 ml THF. The Boc anhydride solution
was added dropwise over a period of 30 minutes into the basic
L-lysine solution. The reaction mixture was then heated to 45°C
under a nitrogen atmosphere and stirred for three hours, before the
solvent was removed in vacuo.
The remaining residue was dissolved in deionised water (100 ml)
and washed with cyclohexane (50 ml), before the aqueous layer was
acidified to pH 3 using 1.33M NaHSO4 and the solvent removed in
vacuo. The product is an hygroscopic, pale pink crystalline solid.
(2.14g, 6.18 mmol, 43.05%) D-lysine(Boc)2 (4.40g, 12.70 mmol,
88.44%)
Melting point: 44.4-45.8 °C, D-Lysine(Boc)2 45.1-46.2 °C
Rf = 0.51 (9:1, DCM:methanol, ninhydrin)
1H NMR (400 MHz, CD3OD) δ: 4.07-4.00 (m, CHNH, 1H); 3.89 (dd,
CHaHbNH, 1H); 2.99 (t, CH2NH, 3J = 6.6 Hz, 2H); 1.77-1.73 (m,
CHaHbCHNH, 1H); 1.63-1.55 (m, CHaHbCHNH, 1H); 1.44 (br s,
CH2CH2CH2NH, 2x C(CH3)3, 24H); 1.26-1.17 (m, CH2CH2CH2NH,
1H)
13C NMR (100 MHz, CD3OD) δ: 176.4 (COOH); 158.7 (COONH);
158.3 (COONH); 101.4, 80.6 (C(CH3)3); 80.0 (C(CH3)3); 54.9
(CH2CHNH); 41.1 (CH2CH2NH); 32.6 (CH2CHNH), 30.6
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(CH2CH2NH, 29.0 (C(CH3)3 x3); 28.9 (C(CH3)3 x3); 24.2
(CH2CH2CH2NH).
ESI-MS: 369.19 [M+Na]+ (90%), 347.21 [M+H]+ (20%)
HRMS: L-lysine(Boc)2 Calcd. [M+H]+ (C16H31N2O6) m/z = 347.2177,
found [M+Na]+ m/z = 347.2170 (error 1.8 ppm)
[M+Na]+ (C16H30N2NaO6) m/z = 369.1996, found [M+Na]+ m/z =
369.1986 (error 3.4 ppm).
HRMS: D-lysine(Boc)2 Calcd. [M+H]+ (C16H31N2O6) m/z =
347.2177, found [M+Na]+ m/z = 347.2182 (error - 0.2 ppm)
[M+Na]+ (C16H30N2NaO6) m/z = 369.1996, found [M+Na]+ m/z =
369.1993 (error 0.9 ppm).
IR v [cm-1]: 3343br w (N-H), 2977m (C-H), 2934m (C-H), 2869m
(C-H), 1683s (CONH), 1520m, 1517m (CONH), 1452m, 1413m,
1392m, 1366s, 1249m, 1160s, 1049m, 1019m, 861m.
Synthesis of C16-L-Ala(Boc) and C16-D-Ala(Boc)
N
H
O
NHO
O
H3C
C16-L-Ala(Boc)
C24H48N2O3
Molecular weight: 412.66
L-Ala-(Boc)2 (275 mg, 1.44 mmol) was dissolved in DCM (40 ml)
before TBTU (463 mg, 1.44 mmol) and NEt3 (5 ml) were added. The
mixture was stirred for 5 minutes before 1-hexadecylamine (390 mg,
1.44 mmol) in DCM (20 ml) was added to the solution and left
stirring overnight. The solvent was removed in vacuo and the
remaining residue redissolved in DCM (50 ml) before being washed
with 1.33 M NaHSO4 (2 x 15 ml), saturated NaHCO3 (2 x 15 ml),
water (3 x 15 ml) and saturated NaCl (15 ml). After purification by
column chromatography, (SiO2 in n-hexane: ethyl acetate 1:1) and
solvent removed in vacuo, the product was obtained as a white
solid. (306 mg, 0.74 mmol, 51.47%) C16-D-Ala(Boc) (398 mg, 0.97
mmol, 66.87%)
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Rf = 0.73 (1:1, n-hexane: ethyl acetate, KMnO4)
1H NMR (400 MHz, CDCl3) δ: 6.17 (br s, CH3CHCONH, 1H); 5.01
(br s, CHNHCOOBoc, 1H); 4.12-4.08 (m, CH3CHNH, 1H); 3.24 (q,
CONHCH2, 3J = 6.4 Hz x3, 2H); 1.72 (s, CH2CH2NH, 2H); 1.48 (br d,
CH2CH2CH2, 3J = 6.4 Hz, 2H); 1.45 (d, C(CH3)3, 9H); 1.36 (d,
NHCH2CHaHb, 3J = 1.92 Hz, 1H); 1.34 (br d,CH3CHCONH, 3J = 1.4
Hz, 3H); 1.26 (s, CH2CH2CH2, 24H); 0.89 (app t, CH2CH2CH3, 3J = 3
Hz, 3H).
13C NMR (100 MHz, CDCl3) δ: 172.4 (COOH); 155.6 (COOH); 99.9;
80.1 (C(CH3)3); 50.0 (CH3CHCONH); 39.5 (CH2NH); 31.9
(CH2CH2CH3); 29.7 (CH2CH2CH2 x4); 29.6 (CH2CH2CH2 x2); 29.6
(CH2CH2CH2); 29.5 (CH2CH2CH2 x2); 29.3 (CH2CH2CH2); 29.3
(CH2CH2CH2); 28.3 (C(CH3)3 x3); 26.8 (CH2CH2CH2NH); 22.7
(CH2CH3); 18.3 (CH3CHCONH); 14.1 (CH2CH3).
ESI-MS: 435.35 [M+Na]+ (100%), 413.37 [M+H]+ (50%).
HRMS: C16-L-Ala(Boc) Calcd. [M+H]+ (C24H49N2O3) m/z =
413.3738 , found [M+H]+ m/z = 413.3719 (error 4.4 ppm)
[M+Na]+ (C24H48N2NaO3) m/z = 435.3557, found [M+Na]+ m/z =
435.3535 (error 5.3 ppm).
HRMS: C16-D-Ala(Boc) Calcd. [M+Na]+ (C24H48N2NaO3) m/z =
435.3557, found [M+Na]+ m/z = 435.3546 (error 3.7 ppm).
IR v [cm-1]: 3344w (N-H), 3317m (N-H), 3261m (N-H), 3075w (C-H),
2983m (C-H), 2956m (C-H), 2917s (C-H), 2848s (C-H), 1734w (C=O),
1713w (C=O), 1687s (CONH), 1650s (CONH), 1613w, 1553m, 1532s
(CONH), 1469m, 1454m, 1384m, 1365m, 1322m, 1250s, 1214m, 1172s,
1115m, 1067m, 1040m, 1026m, 867m.
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Synthesis of C16-L-Ala and C16-D-Ala
N
H
O
NH2
H3C
.HCl
C16-L-Ala .HCl
C19H40N2O .HCl
Molecular weight: 348.29
C16-L-Ala(Boc) (146.20 mg, 0.35 mmol was dissolved in 4M HCl in
dioxane (1.32 ml, 15 eq.) The solution was left stirring for 1 hour
before the solvent was removed in vacuo to give the product as a
white foam. (90.81 mg, 0.26 mmol, 73.59%) C16-D-Ala (325 mg, 0.93
mmol, 97.48%)
1H NMR (400 MHz, CD3OD) δ: 3.89-3.84 (m, CH3CHCONH, 1H);
3.26-3.14 (m, CH2NH, 2H); 1.53-1.46 (m, CH3CHCONH +
CH2CH2NH, 5H); 1.40-1.23 (m, CH2CH2CH2, 24H); 0.88 (br t,
CH2CH3, 3J = 6.3 Hz, 3H).
13C NMR (100 MHz, CD3OD) δ: 170.9 (CONH); 101.5, 50.4
(CH3CHNH2); 40.8 (CH2CH2NH); 33.2 (CH2CH2CH3); 30.9, 30.9,
30.8, 30.6, 30.6, 30.5, all (CH2CH2CH2 x 11); 28.1 (CH2CH2CH2NH);
23.9 (CH2CH3); 17.9 (CH3CHNH2); 14.6 (CH2CH3).
ESI-MS: 335.30 [M+Na]+ (20%), 313.32 [M+H]+ (100%).
HRMS: C16-L-Ala Calcd. [M+H]+ (C19H41N2O) m/z = 313.3213,
found [M+H]+ m/z = 313.3209 (error 2.3 ppm).
[M+Na]+ (C19H40N2NaO) m/z = 335.3033, found [M+Na]+ m/z =
335.3033 (error - 0.8 ppm).
HRMS: C16-D-Ala Calcd. [M+H]+ (C19H41N2O) m/z = 313.3213,
found [M+H]+ m/z = 313.3208 (error 0.2 ppm).
IR v [cm-1]: 3346w (N-H), 3318m (N-H), 3261w (N-H), 2985w (C-H),
2956m (C-H), 2917s (C-H), 2849s (C-H), 1689s (CONH), 1676m
(CONH), 1652s (CONH), 1526s (CONH), 1471s, 144m, 1365m,
1320m, 1250m, 1229m, 1170m, 1125m, 1065m, 1031m, 955w, 934w,
896w, 860m,
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Synthesis of C16-L-Ala-L-Lys(Boc)2 and
C16-D-Ala-D-Lys(Boc)2
N
H
O
NH
H3C
O
HN
O
O
N
H
O
O
C16-L-Ala-L-Lys(Boc)2
C35H68N4O6
Molecular weight: 640.51
L-Lys(Boc)2 (101 mg, 0.29 mmol) was dissolved in DCM (40 ml)
before TBTU (93 mg, 0.29 mmol) and NEt3 (5 ml) were added. The
solution was left stirring for 5 minutes before C16-L-Ala (91 mg, 0.26
mmol) in DCM (20 ml) was added. The solution was left stirring
overnight, before solvent was removed in vacuo.
The remaining residue was redissolved in DCM (50 ml) before being
washed with 1.33 M NaHSO4 (2 x 15 ml), saturated NaHCO3 (2 x 15
ml), water (3 x 15 ml) and saturated NaCl (15 ml). The solvent was
removed in vacuo, and the product obtained as a pale orange solid.
(150 mg, 0.23 mmol, 88.46%) C16-D-Ala-D-Lys(Boc)2 pale yellow
solid (151 mg, 0.24 mmol, 90.67%)
1H NMR (400 MHz, CDCl3) δ: 6.71-6.47 (br s, CH2NHCOOBoc +
CHNHCOOBoc, 2H) 5.58-5.43 (m, CH2NHCOCH, 1H); 4.72 (br s,
CONHCHCO, 1H); 4.43 (quint., CH3CHNHCONH, 3J = 7.2 Hz x4,
1H); 4.00 (br d, CH2CHNHCOOBoc, 3J = 4.1 Hz, 1H); 3.31-3.18 (m,
CH2CH2NHCOOBoc, 2H); 3.18-3.05 (m, CH2CH2NHCOCH, 2H);
1.76 (br s, CH2CHNH, 2H); 1.58-1.48 (m, CH2CH2NHCO, 4H);
1.46-1.43 (m, COOC(CH3)3, 18H); 1.37 (d, CH3CHCONH, 3J= 7.2 Hz,
3H); 1.36-1.31 (m, CH2CH2CH, 2H); 1.30-1.21 (m, CH2CH2CH2,
24H); 0.91-0.85 (m, CH2CH3, 3H).
13C NMR (100 MHz, CDCl3) δ: 171.8 (CHCONH); 166.9
(CH3CHCONH); 157.3 (COONH); 156.6 (COONH); 80.5 (C(CH3)3
x2); 53.9 (CH2CHNH); 48.9 (CH3CHNH); 39.7 (CH2CH2NH); 38.6
(CH2CH2NH); 31.9 (CH2CH2CH3); 29.7 (CH2CH2NH); 29.6
(CH2CH2CH2 x4); 29.6 (CH2CH2CH2 x2); 29.5 (CH2CH2CH2); 29.3
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(CH2CH2CH2 x2); 29.3 (CH2CH2CH2); 28.5 (C(CH3)3 x3); 28.3
(C(CH3)3 x3); 26.8 (CH2CH2CH2NH); 22.7 (CH2CH3); 22.2
(CH2CH2CHNH); 18.1 (CHCH3); 14.1 (CH2CH3).
ESI-MS: 663.50 [M+Na]+ (100%).
HRMS: C16-L-Ala-L-Lys(Boc)2 Calcd. [M+Na]+ (C35H68N4NaO6)
m/z = 663.5031, found [M+Na]+ m/z = 663.5044 (error -1.9 ppm).
HRMS: C16-D-Ala-D-Lys(Boc)2 Calcd. [M+H]+ (C35H68N4O6) m/z =
641.5390, found [M+H]+ m/z = 641.5212.
IR v [cm-1]: 3293br m (N-H), 2919m (C-H), 2851m (C-H), 1686m
(CONH), 1643s (CONH), 1525s (CONH), 1467m, 1454m, 1365m,
1273m, 1247m, 1168s, 1102w, 1048m, 966w, 923w, 867w.
Synthesis of C16-D-Ala-L-Lys(Boc)2 and
C16-L-Ala-D-Lys(Boc)2
N
H
O
NH
H3C
O
HN
O
O
N
H
O
O
C16-D-Ala-L-Lys(Boc)2
C35H68N4O6
Molecular weight: 640.51
L-Lys(Boc)2 (348 mg, 1.005 mmol) was dissolved in DCM (40 ml)
before TBTU (323 mg, 1.005 mmol) and NEt3 (9 ml) were added.
The solution was left stirring for 5 minutes before C16-D-Ala (314
mg, 0.90 mmol) in DCM (20 ml) was added. The solution was left
stirring overnight, before solvent was removed in vacuo.
The remaining residue was redissolved in DCM (50 ml) before being
washed with 1.33 M NaHSO4 (2 x 25 ml), saturated NaHCO3 (2 x 25
ml), water (3 x 25 ml) and saturated NaCl (25 ml). The solvent was
removed in vacuo, and the product obtained as a pale orange solid.
(340 mg, 0.53 mmol, 58.98%) C16-L-Ala-D-Lys(Boc)2 (152 mg, 0.31
mmol, 86.36%).
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1H NMR (400 MHz, CCl3) δ: 6.64-6.47 (br s, CH2NHCOOBoc +
CHNHCOOBoc, 2H); 5.24-5.17 (m, CH2NHCOCH, 1H); 4.67-4.60
(m, CONHCHCO, 1H); 4.48-4.39 (m, CH3CHNHCONH, 1H);
4.04-3.93 (m, CH2CHNHCOOBoc, 1H); 3.30-3.17 (m,
CH2CH2NHCOOBoc, 2H); 3.17-3.08 (m,CH2CH2NHCOCH, 2H);
1.70-1.68 (br s, CH2CHNH, 2H); 1.58-1.48 (m, CH2CH2NHCO, 4H);
1.47-1.43 (m, COOC(CH3)3, 18H); 1.37 (d, CH3CHCONH, 3J= 7.2 Hz,
3H); 1.25 (br d, CH2CH2CH2, 3J = 1.8 Hz, 22H); 0.91-0.86 (m,
CH2CH3, 3H)
13C NMR (100 MHz, CCl3) δ: 171.6 (CHCONH); 170.5
(CH3CHCONH); 167.3 (COONH); 166.2 (COONH); 78.8 (C(CH3)3
x2); 50.9 (CH2CHNH); 48.9 (CH3CHNH); 39.7 (CH2CH2NH); 38.9
(CH2CH2NH); 31.9 (CH2CH2CH3); 29.7 (CH2CH2NH); 29.70
(CH2CH2CH2); 29.6 (CH2CH2CH2 x4); 29.5 (CH2CH2CH2 x2); 29.5
(CH2CH2CH2); 29.4 (CH2CH2CH2 x2); 29.2 (CH2CH2CH2); 28.4
(C(CH3)3 x3); 28.3 (C(CH3)3 x3); 26.9 (CH2CH2CH2NH); 22.7
(CH2CH3); 22.5 (CH2CH2CHNH); 18.2 (CHCH3); 14.1 (CH2CH3).
ESI-MS: 663.50 [M+Na]+ (100%), 641.52 [M+H]+ (10%)
HRMS: C16-D-Ala-L-Lys(Boc)2 Calcd. [M+H]+ (C35H69N4O6) m/z =
641.52116, found [M+H]+ m/z = 641.51812 (error 4.0 ppm),
[M+Na]+ (C35H68N4NaO6) m/z = 663.5031, found [M+Na]+ m/z =
663.5020 (error 2.2 ppm).
HRMS: C16-L-Ala-D-Lys(Boc)2 Calcd. [M+Na]+ (C35H68N4NaO6)
m/z = 663.5031, found [M+Na]+ m/z = 663.5028 (error 0.3 ppm).
IR v [cm-1]: 3292br m (N-H), 2919m (C-H), 2851m (C-H), 1687m
(CONH), 1657m (CONH), 1639s (CONH), 1520m (CONH), 1454m,
1391m, 1365m, 1271m, 1245s, 1168s, 1056m, 868m.
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Synthesis of C16-L-Ala-L-Lys
N
H
O
NH
H3C
H2N
O
NH2
C16-L-Ala-L-Lys
C25H52N4O2
Molecular weight: 440.41
C16-L-Ala-L-Lys(Boc)2 (143 mg, 0.22 mmol) was dissolved in
methanol, before HCl gas was bubbled through the solution for 30
seconds and stirred for 3 hours. The solvent was removed in vacuo
to afford the product as a bright orange solid. 40 mg, 0.09 mmol,
41.20% yield.
Melting point: 257.2-263.6 °C
1H NMR (400 MHz, CD3OD) δ: 4.32 (br d, CH3CHCONH, 3J= 7.3
Hz, 1H); 3.91 (br t, CH2CHNH2,3J = 6.2 Hz, 1H); 3.23-3.15 (m,
CHaHbNHCOCH, 1H); 3.15-3.08 (m, CHaHbNHCOCH, 1H); 2.96 (br
t, CH2CH2NH2, 3J = 6.9 Hz, 2H); 1.91-1.86 (m, CH2CHNH, 2H); 1.73
- 1.67 (br s, CH2CH2CHNH2, 2H); 1.50-1.44 (m, CH2CH2NH2, 2H);
1.36-1.31 (m, CH3CHCONH, 3H); 1.26 (s, CH2CH2CH2, 18H);
0.87-0.85 (m, CH2CH3, 3H).
13C NMR (100 MHz, CD3OD) δ: 174.7 (CHCONH); 169.8
(CH3CHCONH); 54.0 (CH2CHNH2); 50.8 (CHCH3); 40.7
(CH2CH2NH2); 40.4 (CH2CH2NH); 33.2 (CH2CHNH2); 32.1
(CH2CH2CH3); 30.9, 30.9, 30.6, 30.6 ( all CH2CH2CH2 x 11); 30.5
(CH2CH2NH); 28.1 (CH2CH2CH2NH); 23.9 (CH2CH3); 22.5
(CH2CH2NH2); 18.5 (CHCH3); 14.6 (CH2CH3);
ESI-MS: 441.41 [M+H]+ (100%).
HRMS: Calcd. [M+H]+ (C25H53N4O2) m/z = 441.4163, found
[M+H]+ m/z = 441.4151 (error 3.2 ppm).
IR v [cm-1]: 3392br w (N-H), 2919m (C-H), 2851m (C-H), 1662m
(CONH), 1639s (CONH), 1563m, 1558m (CONH), 1464s, 1376m,
1293w, 1286w, 1255w, 1153m, 1072w, 976w, 948w, 888w.
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Synthesis of C16-D-Ala-L-Lys and C16-L-Ala-D-Lys
N
H
O
NH
H3C
H2N
O
NH2
C16-D-Ala-L-Lys
C25H52N4O2
Molecular weight: 440.41
C16-D-Ala-L-Lys(Boc)2 (329 mg, 0.51 mmol) was dissolved in 4 M
HCl in dioxane (1.92 ml, 15 eq). The solution was stirred at room
temperature for 1 hour. The solvent was removed in vacuo to afford
the product as an off-white solid. (270 mg, 0.42 mmol, 82.35%)
C16-L-Ala-D-Lys 152 mg, 0.34 mmol, 81.17%).
Melting point: 255.8-260.5 °C, C16-L-Ala-D-Lys 255.6-260.8 °C
1H NMR (400 MHz, CD3OD) δ: 4.34-4.28 (m, CH3CHCONH, 1H);
3.94-3.91 (m, CH2CHNH2, 1H); 3.19-3.15 (m, CH2NHCO, 2H);
2.97-2.93 (m, CH2CH2NH2, 2H); 1.91-1.80 (m, CH2CH2CHNH2, 2H);
1.74-1.70 (m, CH2CH2CHNH2, 2H); 1.49 (br d CH2CH2NH2, 2H);
1.39 (d, CH3CHCONH, 3J = 7.3 Hz, 3H); 1.26 (br s, CH2CH2CH2,
24H); 0.91-0.84 (m, app t, CH2CH3, 3H).
13C NMR (100 MHz, CD3OD) δ: 173.3 (CHCONH); 169.9
(CH3CHCONH); 54.4 (CH2CHNH2); 50.9 (CHCH3); 40.7
(CH2CH2NH2); 40.4 (CH2CH2NH); 33.2 (CH2CHNH2); 32.1
(CH2CH2CH3); 30.9, 30.9, 30.8, 30.6 (all CH2CH2CH2 x 11); 30.5
(CH2CH2NH); 28.3 (CH2CH2CH2NH); 23.9 (CH2CH3); 23.2
(CH2CH2NH2); 18.6 (CHCH3); 14.6 (CH2CH3);
ESI-MS: 441.41 [M+H]+ (100%)
HRMS: C16-D-Ala-L-Lys Calcd. [M+H]+ (C25H53N4O2) m/z =
441.4163, found [M+H]+ m/z = 441.4175 (error -2.9 ppm).
HRMS: C16-L-Ala-D-Lys Calcd. [M+H]+ (C25H53N4O2) m/z =
441.4163, found [M+H]+ m/z = 441.4148 (error 4.8 ppm).
IR v [cm-1]: 3398br w (N-H), 2955w (C-H), 2917m (C-H), 2850m
(C-H), 1638s (CONH), 1557w (CONH), 1467s, 1376m, 1271w, 1254w,
1234w, 1213m, 1160m, 1056m, 979w.
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Synthesis of C16-D-Ala-D-Lys
N
H
O
NH
H3C
H2N
O
NH2
C16-D-Ala-D-Lys
C25H52N4O2
Molecular weight: 440.41
C16-D-Ala-D-Lys(Boc)2 (141 mg, 0.22 mmol) was dissolved in 4 M
HCl in dioxane (0.82 ml, 15 eq). The solution was stirred at room
temperature for 1 hour. The solvent was removed in vacuo to afford
the product as an of-white solid. (112 mg, 0.25 mmol, 95.00%)
Melting point: 261.7-263.7 °C
1H NMR (400 MHz, CD3OD) δ: 4.35-4.21 (m, CH3CHNH, 1H);
3.93-3.82 (m, CH2CHNH2, 1H); 3.21-3.00 (m CH2CH2NH, 2H);
2.98-2.84 (m, CH2CH2NH2, 2H); 1.92-1.78 (m, CH2CHNH2, 2H);
1.74-1.61 (m, CH2CH2CH2NH2, 2H); 1.58-1.41 (m, CH2CH2NH2,
2H); 1.39-1.35 (m, CH3CHCONH, 3H); 1.26 (s, CH2CH2CH2, 24H);
0.89-0.85 (m, CH2CH3, 3H).
13C NMR (100 MHz, CD3OD) δ: 174.7 (CHCONH); 169.8
(CH3CHCONH); 54.0 (CH2CHNH2); 50.8 (CHCH3); 40.6
(CH2CH2NH2); 40.6 (CH2CH2NH); 33.2 (CH2CHNH2); 32.0
(CH2CH2CH3); 30.9, 30.9, 30.6, 30.6 (all CH2CH2CH2 x 11); 30.5
(CH2CH2NH); 28.1 (CH2CH2CH2NH); 23.9 (CH2CH3); 22.5
(CH2CH2NH2); 18.5 (CHCH3); 14.6 (CH2CH3);
ESI-MS: 441.41 [M+H]+ (100%).
HRMS: Calcd. [M+H]+ (C25H53N4O2) m/z = 441.4163, found
[M+H]+ m/z = 441.4182 (error -3.1 ppm).
IR v [cm-1]: 3291br m (N-H), 2954m (C-H), 2918s (C-H), 2872m (C-H),
2850m (C-H), 1683m (CONH), 1641s (CONH), 1557w, 1524m
(CONH), 1467s, 1376m, 1271w, 1254w, 1234w, 1213m, 1160m, 1056m,
979w.
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5.3 Assay Methods and Materials
All materials used in the spectroscopic assays outlined below, with
the exception of the novel compounds and Mallard Blue, are
obtained from commercial sources and used without further
purification, unless otherwise stated.
Sodium salt heparin from porcine intestinal mucosa with a
molecular weight between 15,000 ± 2,000 Da (1 KU = 1000 units)
was obtained from Calbiochem.
All spectroscopic assay measurements are performed in triplicate.
Nile Red Assay
Buffer solution was prepared by dissolving Tris HCl (2.5 ml, 10 mM)
and NaCl (2.1915 g, 150 mM) in Mili-Q water (250 ml).
A binder stock solution was prepared by dissolving sufficient binder
in Tris HCl buffer to give a final concentration of either 100 or 300
µM. This stock solution was then incubated at 45°C for 10 minutes.
Nile Red solution was prepared by dissolving sufficient Nile Red
into ethanol to give a final concentration of 2.5 mM.
In a cuvette, this stock solution was diluted with Tris-HCl buffer to
give the required concentrations, with a final assay volume of 1 ml.
To each cuvette, 1µL of Nile Red was added, before inversion to
ensure complete mixing. Fluorescence intensity was recorded at 635
nm using a 550 nm excitation wavelength.
Mallard Blue
A buffer solution containing Tris HCl (2.5 ml, 10 mM) and NaCl
(2.1915 g, 150 mM) was prepared in Mili-Q water (250 ml).
A stock solution of Mallard Blue (MalB) was prepared by dissolving
Mallard Blue (1.805 mg, 25 µM) in the previously prepared buffer
solution (100 ml). The Mallard Blue solution was then incubated at
50°C for 24 hours, or until it turns a deep blue colour.
A heparin stock solution was prepared by dissolving heparin (0.899
mg, 27 µM) into 50 ml of Mallard Blue and buffer solution.
To prepare the binder solution, sufficient binder (2.39 mg) was
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added to pre-prepared heparin and MalB solution (5 ml), so that
after the addition of 10 µl of this solution to the cuvette, the charge
ratio of the cuvette is 0.1.
Each cuvette was filled with 2 ml of heparin + MalB solution before
10 µL of binder solution was added, and the cuvette was inverted to
ensure good mixing. The absorbance at 615 nm was measured.
After each addition, the cuvette was inverted to ensure good mixing
and the absorbance at 615 nm was recorded against a Tris HCl (10
mM) baseline. Absorbance was normalised between a solution of
MalB (25 µM), NaCl (150 mM) in Tris HCl (10 mM) and one
containing MalB (25 µM), heparin (27 µM), NaCl (150 mM) in Tris
HCl (10 mM).
Ethidium Bromide Displacement Assay
A buffer solution containing Tris HCl (2.5 ml, 10 mM) and NaCl
(2.1915 g, 150 mM) was prepared in Mili-Q water (250 ml).
The Ethidium Bromide (EthBr) stock solution was prepared by
dissolving EthBr (1 mg) into buffer solution (100 ml) to give a final
concentration of 25.4 µM.
A DNA stock solution was prepared by dissolving DNA (1 mg) into
buffer solution (100 ml) to give a final concentration of 30.3 µM.
Diluted solutions of both DNA and EthBr were made. An 8 µM
solution of DNA was prepared by mixing 13.2 ml DNA stock
solution with sufficient buffer solution to reach a final volume of
50ml.
A 10.14 µM solution of EthBr was prepared by mixing 20 ml of
EthBr stock solution with further buffer to give a final volume of 50
ml.
The binder stock solution was prepared in a 50:50 solution of
diluted DNA and EthBr, so that final concentrations of DNA and
EthBr were 4.0 µM and 5.07 µM respectively. Sufficient binder was
added to the solution, so that the charge ratio of the binder solution
(+ : -) was 0.1.
The cuvettes were each charged with 1ml of 50:50 diluted DNA &
EthBr solution before the binder stock solution was titrated into
each cuvette (10 µL, 20 µL etc.). After each addition, the cuvette was
inverted to ensure good mixing and the fluorescence at 595 nm was
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recorded using a 540 nm excitation wavelength.
Fluorescence intensities were normalised between two solutions,
one containing 5.07 µM EthBr and 4.0 µM DNA in Tris HCl buffer
and one containing only 5.07 µM EthBr in buffer.
TEM Imaging
Solutions of binder were made by dissolving sufficient binder in
MilliQ water to give a concentration of 2.27 mM. Solutions of DNA
and heparin sulfate were made by dissolving sufficient amounts of
compound in MilliQ water to give final concentrations of 0.6 mM
and 0.35 mM respectively. Equal volumes of DNA solution or
heparin sulfate solution were mixed with binder solution, before
being imaged on a formvar grid, negatively stained with 1% uranyl
acetate.
Circular Dichroism
Solutions of all target compounds were made by dissolving
sufficient binder into a solution of Tris HCl (10 mM) and NaCl (150
mM) to give a final concentration of 2.27 mM.
For the compounds which did not dissolve fully in the buffer, these
solutions were spun at 13000 RPM for 3 minutes and the
supernatant taken for analysis.
Absorbance intensities were normalised against a solution of Tris
HCl (10 mM) and NaCl (150 mM). A further spectrum of the buffer
solution was taken after each sample had been ran to rule out
contamination of the cuvette.
The following settings were used:
Wavelength range: 200-400 nm
Data pitch: 0.5 nm
Scanning: Continuous
Scanning speed: 100 nm/ min
Response: 1s
Bandwidth: 2nm
Accumulation: 5
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List of Abbreviations
ATIII Antithrombin III
CAC Critical Aggregation Concentration
Cas9 CRISPR associated gene 9
CD Circular Dichroism
CF Cystic Fibrosis
CFTR Cystic Fibrosis Transmembrane Conductance Regulator
CRISPR Clustered Regularly Interspaced Short Palindromic Repeat
DCM Dichloromethane
DLS Dynamic Light Scattering
DNA Deoxyribose Nucleic Acid
DOTMA N-[1(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride
DOSPA 2,3-dioleyloxy-N-[2(sperminecarboxido)ethyl]-N,N,-dimethyl-1-
propanaminium trifluoroacetate
DVT Deep Vein Thrombosis
EthBr Ethidium Bromide
FEV1 Forced Expiratory Volume in 1 Second
GTMAC Glycidyltrimethylammonium chloride
HCl Hydrochloric Acid
HIP Heparin Interacting Protein
HIPAP Heparin Interacting Protein Analogue Peptide
IR Infrared Spectroscopy
ITC Isothermal Titration Calorimetry
LMWH Low Molecular Weight Heparin
MalB Mallard Blue
MeOH Methanol
MS Mass Spectrometry
NMR Nuclear Magnetic Resonance
NOAC Novel Oral Anticoagulant
PAH Poly(allylamine hydrochloride)
PAMAM Polyamidoamine
PBS Phosphate Buffered Saline
PEI Polyethyleneimine
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PLL Poly-L-Lysine
sgRNA single guide RNA
SAMul Self Assembled Multivalency
TBTU N,N,N’,N’-Tetramethyl-O-(benzotriazol-1-yl)uronium
tetrafluoroborate
TEM Transmission Electron Microscopy
UFH Unfractionated Heparin
UV Ultraviolet
vCJD variant Creutzfeld-Jakob Disease
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Appendix A
Dynamic Light Scattering
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FIGURE A.1: Intensity distribution of a 0.25 mg ml-1
sample of C16-D-Ala-D-Lys
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FIGURE A.2: Volume distribution of a 0.25 mg ml-1
sample of C16-D-Ala-D-Lys
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FIGURE A.3: intensity distribution of a 1 mg ml-1 sam-
ple of C16-D-Ala-D-Lys
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FIGURE A.4: Intensity distribution of a 0.25 mg ml-1
sample of C16-L-Ala-L-Lys
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FIGURE A.5: Volume distribution of a 0.25 mg ml-1
sample of C16-L-Ala-L-Lys
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FIGURE A.6: Intensity distribution of a 1 mg ml-1 sam-
ple of C16-L-Ala-L-Lys
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FIGURE A.7: Volume distribution of a 1 mg ml-1 sam-
ple of C16-L-Ala-L-Lys
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FIGURE A.8: Volume distribution of a 1 mg ml-1 sam-
ple of C16-D-Ala-D-Lys
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FIGURE A.9: Intensity distribution of a 1.0 mg ml-1
sample of C16-L-Ala-D-Lys
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FIGURE A.10: Volume distribution of a 1.0 mg ml-1
sample of C16-L-Ala-D-Lys
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FIGURE A.11: Intensity distribution of a 0.25 mg ml-1
sample of C16-L-Ala-D-Lys
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FIGURE A.12: Volume distribution of a 0.25 mg ml-1
sample of C16-L-Ala-D-Lys
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FIGURE A.13: Intensity distribution of a 0.25 mg ml-1
sample of C16-D-Ala-L-Lys
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FIGURE A.14: Volume distribution of a 0.25 mg ml-1
sample of C16-D-Ala-L-Lys
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FIGURE A.15: Intensity distribution of a 1 mg ml-1
sample of C16-D-Ala-L-Lys
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FIGURE A.16: Volume distribution of a 1 mg ml-1 sam-
ple of C16-D-Ala-L-Lys
TABLE A.1: A summary of the data obtained by DLS
for each compound.
Compound name Concentration / mg ml-1 Z-Average / nm
C16-L-Ala-L-Lys 0.25 63.66 ± 1.56
C16-L-Ala-L-Lys 1.0 53.25 ± 1.10
C16-D-Ala-D-Lys 0.25 66.52 ± 1.03
C16-D-Ala-D-Lys 1.0 52.90 ± 1.12
C16-L-Ala-D-Lys 0.25 100 ± 13.78
C16-L-Ala-D-Lys 1.0 179.5 ± 4.79
C16-D-Ala-L-Lys 0.25 29.97 ± 1.70
C16-D-Ala-L-Lys 1.0 7912 ± 1815
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